[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2015012924A2 - Tissue preferential codon modified expression cassettes, vectors containing same, and use thereof - Google Patents

Tissue preferential codon modified expression cassettes, vectors containing same, and use thereof Download PDF

Info

Publication number
WO2015012924A2
WO2015012924A2 PCT/US2014/035880 US2014035880W WO2015012924A2 WO 2015012924 A2 WO2015012924 A2 WO 2015012924A2 US 2014035880 W US2014035880 W US 2014035880W WO 2015012924 A2 WO2015012924 A2 WO 2015012924A2
Authority
WO
WIPO (PCT)
Prior art keywords
seq
orf
expression
expression cassette
modified
Prior art date
Application number
PCT/US2014/035880
Other languages
French (fr)
Other versions
WO2015012924A3 (en
Inventor
James M. Wilson
Anna Tretiakova
Original Assignee
The Trustees Of The University Of Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Trustees Of The University Of Pennsylvania filed Critical The Trustees Of The University Of Pennsylvania
Priority to US14/787,622 priority Critical patent/US9719106B2/en
Publication of WO2015012924A2 publication Critical patent/WO2015012924A2/en
Publication of WO2015012924A3 publication Critical patent/WO2015012924A3/en
Priority to US15/627,805 priority patent/US10647998B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Definitions

  • FIG. 2 is a bar chart illustrating AAV-mediated expression of gene constructs modified according to 12 different schemas as compared to a base vector containing the original parental sequence.
  • the codon frequencies used for those modifications are shown in the Tables 1-12, and the parent codon frequency is shown in Table 13.
  • Table 14 shows the codon frequencies which are used in most mammalian codon optimization protocols.
  • Constructs were packaged into AAV8 vector using triple transfection production method in HEK293 cells and purified by tangential flow filtration followed by gradient centrifugation. Viral titer was determined by qPC . 2 x10 GC(genome copies)/mouse were administered intramuscularly in 30 ⁇ injection into RAG KO mice. For bronchial lavage 8 x 10 10 GC/mouse were administered by intranasal instillation in 50 ⁇ into C57B16 mice. For IM injections, blood samples were collected weekly for 2 months via orbital bleeding, and serum was assayed by ELISA.
  • Codon refers to a DNA sequence that encodes a specific amino acid sequence.
  • An open reading frame is a continuous sequence of DNA that contains a start codon, a subsequent region which usually has a length which is a multiple of 3 nucleotides, and a stop codon in the same reading frame.
  • the DNA sequence can be modified by nucleotide substitutions without altering the amino acid sequence of the encoded protein. Such changes are referred to herein as synonymous codon modifications.
  • Base combinations which encode some of the standard amino acids are provided below.
  • the nucleic acid sequence encoding the product is modified with synonymous codon sequences in a tissue-preferential manner.
  • the entire length of the open reading frame (ORF) for the product is modified.
  • only a fragment of the ORF may be altered.
  • the codons are generated based on the codon frequency of a selected table, or a frequency within about 10%, within about 5%, within about 3%, or within about 1% of the codon frequency of any one of the Tables provided herein.
  • “within about 10% frequency” may encompass the frequency of codons for a selected amino acid (e.g., Ala) within a selected Table, or the codon frequencies within a selected Table may be within 10% for each represented amino acid within a selected Table.
  • codon frequencies By utilizing a codon frequency selected from one or more of the Tables 3-12, 16, 17, or a frequency within about 10% thereof (or optionally Table 13, 14 or 15), one can apply the codon frequencies to a selected polypeptide sequence, and produce a nucleic acid fragment of a codon-optimized coding region which encodes the polypeptide, but which uses codons more optimal for a given tissue.
  • the entire length of the open reading frame (ORF) for the product is modified. However, in some embodiments, only a fragment of the O F may be altered.
  • the codon frequency of Table 5 or Table 6, or a codon frequency within 10% thereof is particularly well suited to enhance expression of a selected gene product in muscle, and more particularly, skeletal muscle.
  • the codon frequency of Table 9, Table 10, or Table 11, or a codon frequency within 10% thereof is particularly well suited to enhance expression of a selected gene product in liver.
  • the codon frequency of Table 16 is particularly well suited to enhance expression of a selected gene product in respiratory epithelium (e.g., lung).
  • expression is mediated by an AAV.
  • the codon frequency of these tables are useful in other methods and for other delivery vectors.
  • the methods provided herein are designed as the primary consideration to select the frequently used codon for a given amino acid as the primary consideration. However, as a secondary or tertiary consideration, the methods described herein may further select a codon or modify a selected sequence to exclude undesirable structural elements, e.g., (a) restriction sites, CpG islands, (b) exclusion of a hairpin turn in the initial polynucleotide sequence; (c) exclusion of a repeat element in the initial polynucleotide sequence; (d) exclusion of a ribosome binding site in the initial polynucleotide sequence; (e) exclusion of a codon or modify a selected sequence to exclude undesirable structural elements, e.g., (a) restriction sites, CpG islands, (b) exclusion of a hairpin turn in the initial polynucleotide sequence; (c) exclusion of a repeat element in the initial polynucleotide sequence; (d) exclusion of a ribosome binding site in
  • oligonucleotide pairs are synthesized such that upon annealing, they form double stranded fragments of 80-90 base pairs, containing cohesive ends, e.g., each oligonucleotide in the pair is synthesized to extend 3, 4, 5, 6, 7, 8, 9, 10, or more bases beyond the region that is complementary to the other oligonucleotide in the pair.
  • the single- stranded ends of each pair of oligonucleotides is designed to anneal with the single-stranded end of another pair of oligonucleotides.
  • the inserts of these plasmids are then cut with appropriate restriction enzymes and ligated together to form the final construct.
  • the final construct is then cloned into a standard bacterial cloning vector, and sequenced. Additional methods would be immediately apparent to the skilled artisan. In addition, gene synthesis is readily available commercially.
  • nucleic acids or polypeptide sequences refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same (i.e., about 70% identity, preferably 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or higher identity) over a specified region (e.g., any one of the modified ORFs provided herein when compared and aligned for maximum correspondence over a comparison window or designated region) as measured using a BLAST or BLAST 2.0 sequence comparison algorithms with default parameters described below, or by manual alignment and visual inspection (see, e.g., NCBI web site or the like).
  • a specified region e.g., any one of the modified ORFs provided herein when compared and aligned for maximum correspondence over a comparison window or designated region
  • polynucleotide sequences can be compared using Fasta, a program in GCG Version 6.1.
  • Fasta provides alignments and percent sequence identity of the regions of the best overlap between the query and search sequences.
  • percent sequence identity between nucleic acid sequences can be determined using Fasta with its default parameters (a word size of 6 and the NOP AM factor for the scoring matrix) as provided in GCG Version 6.1, herein incorporated by reference.
  • these programs are used at default settings, although one skilled in the art can alter these settings as needed.
  • one of skill in the art can utilize another algorithm or computer program that provides at least the level of identity or alignment as that provided by the referenced algorithms and programs. This definition also refers to, or can be applied to, the compliment of a sequence.
  • the definition also includes sequences that have deletions and/or additions, as well as those that have substitutions.
  • the preferred algorithms can account for gaps and the like.
  • identity exists over a region that is at least about 25, 50, 75, 100, 150, 200 amino acids or nucleotides in length, and oftentimes over a region that is 225, 250, 300, 350, 400, 450, 500 amino acids or nucleotides in length or over the full-length of an amino acid or nucleic acid sequences.
  • the alignment when an alignment is prepared based upon an amino acid sequence, the alignment contains insertions and deletions which are so identified with respect to a reference AAV sequence and the numbering of the amino acid residues is based upon a reference scale provided for the alignment.
  • any given AAV sequence may have fewer amino acid residues than the reference scale.
  • the term "the same position" or the "corresponding position” refers to the amino acid located at the same residue number in each of the sequences, with respect to the reference scale for the aligned sequences.
  • each of the proteins when taken out of the alignment, each of the proteins may have these amino acids located at different residue numbers. Alignments are performed using any of a variety of publicly or commercially available Multiple Sequence Alignment Programs.
  • Sequence alignment programs are available for amino acid sequences, e.g., the "Clustal X”, “MAP”, “PIMA”, “MSA”, “BLOCKMAKER”, “MEME”, and “Match-Box” programs. Generally, any of these programs are used at default settings, although one of skill in the art can alter these settings as needed. Alternatively, one of skill in the art can utilize another algorithm or computer program which provides at least the level of identity or alignment as that provided by the referenced algorithms and programs. See, e.g., J. D. Thomson et al, Nucl. Acids. Res., "A comprehensive comparison of multiple sequence alignments", 27(13):2682-2690 (1999).
  • an expression cassette as described herein contains the modified gene which has codons preferentially modified and selected to express a product in a target tissue, which is operably linked to expression control sequences which direct expression thereof.
  • Such an expression cassette may also include expression control sequences useful for transcription initiation, termination, promoter and enhancer sequences; efficient RNA processing signals such as splicing and polyadenylation (polyA) signals; sequences that stabilize cytoplasmic mRNA; sequences that enhance translation efficiency (i.e., Kozak consensus sequence); sequences that enhance protein stability; and when desired, sequences that enhance secretion of the encoded product.
  • polyA polyadenylation
  • sequences that enhance translation efficiency i.e., Kozak consensus sequence
  • sequences that enhance protein stability i.e., Kozak consensus sequence
  • sequences that enhance secretion of the encoded product Alternatively, or additionally, such regulatory expression elements may be located outside of the expression cassette, e.g., within another region of a vector into which the expression cassette is
  • Fig. 5 Provided in Fig. 5 and the sequence listing (SEQ ID Nos: 13-29), herein are the plasmid constructs utilized the Example below.
  • the plasmids contain sequences encoding an anti-HIV antibody (3bcnl 17 antibody. See, Scheid et al, Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science. 2011 Sep 16;333(6049): 1633-7. Epub 2011 Jul 14, which is incorporated herein by reference).
  • Specific fragments of the sequences are identified and are, in one embodiment, of particular interest. These fragments may be used in conjunction with other fragments described herein, or other complementary fragments as known in the art.
  • certain fragments of interest include the constant regions of the heavy and light chains of an antibody such as the anti-SIV or anti-HIV antibody of the examples.
  • These sequences having been optimized for expression in a particular tissue type (e.g., liver, respiratory epithelial cells (e.g., lung)) may be utilized in conjunction with the variable regions of other antibodies, as described further below.
  • the variable regions may be optimized for expression in the desired tissue using the codon frequency tables described herein. See Tables 3 - 12, 16, 17.
  • Tables 2, 23, 24, 15 may be used in conjunction with the methods and constructs described herein.
  • Desirable fragments of the plasmids include 5 ' and 3' IT sequences, promoters, enhancers, TATA box, introns, IRES, F2A linkers, furin sites, forward primers, reverse primers, polyA signals.
  • Other desirable fragments include the following:
  • a nucleotide sequence encoding any of a number of different therapeutic transgenes may be selected for codon modification to enhance tissue-preferential expression as described herein.
  • Useful therapeutic products encoded by the transgene include hormones and growth and differentiation factors including, without limitation, insulin, glucagon, growth hormone (GH), parathyroid hormone (PTH), growth hormone releasing factor (GRF), follicle stimulating hormone (FSH), luteinizing hormone (LH), human chorionic gonadotropin (hCG), vascular endothelial growth factor (VEGF), angiopoietins, angiostatin, granulocyte colony stimulating factor (GCSF), erythropoietin (EPO), connective tissue growth factor (CTGF), basic fibroblast growth factor (bFGF), acidic fibroblast growth factor (aFGF), epidermal growth factor (EGF), platelet-derived growth factor (PDGF), insulin growth factors I and II (IGF-I and IGF-II), any one of
  • transgene products include proteins that regulate the immune system including, without limitation, cytokines and lymphokines such as thrombopoietin (TPO), interleukins (IL) IL-1 through IL-25 (including IL-2, IL-4, IL-12 and IL-18), monocyte chemoattractant protein, leukemia inhibitory factor, granulocyte-macrophage colony stimulating factor, Fas ligand, tumor necrosis factors a and ⁇ , interferons ⁇ , ⁇ , TGFb and ⁇ , stem cell factor, flk-2/flt3 ligand.
  • TPO thrombopoietin
  • IL interleukins
  • IL-1 interleukins
  • IL-25 including IL-2, IL-4, IL-12 and IL-18
  • monocyte chemoattractant protein including IL-2, IL-4, IL-12 and IL-18
  • Fas ligand granulocyte-macrophage colony stimulating factor
  • immunoglobulins IgG, IgM, IgA, IgD and IgE include, without limitations, immunoglobulins IgG, IgM, IgA, IgD and IgE, chimeric immunoglobulins, humanized antibodies, single chain antibodies, T cell receptors, chimeric T cell receptors, single chain T cell receptors, class I and class II
  • MHC molecules as well as engineered immunoglobulins and MHC molecules.
  • Useful gene products also include complement regulatory proteins such as complement regulatory proteins, membrane cofactor protein (MCP), decay accelerating factor (DAF), CRl, CF2 and CD59.
  • complement regulatory proteins such as complement regulatory proteins, membrane cofactor protein (MCP), decay accelerating factor (DAF), CRl, CF2 and CD59.
  • Still other useful gene products include any one of the receptors for the hormones, growth factors, cytokines, lymphokines, regulatory proteins and immune system proteins.
  • the invention encompasses receptors for cholesterol regulation and/or lipid modulation, including the low density lipoprotein (LDL) receptor, high density lipoprotein (HDL) receptor, the very low density lipoprotein (VLDL) receptor, and scavenger receptors.
  • LDL low density lipoprotein
  • HDL high density lipoprotein
  • VLDL very low density lipoprotein
  • the invention also encompasses gene products such as members of the steroid hormone receptor superfamily including glucocorticoid receptors and estrogen receptors, Vitamin D receptors and other nuclear receptors.
  • useful gene products include transcription factors such as jun, fos, max, mad, serum response factor (SRF), AP-1, AP2, myb, MyoD and myogenin, ETS-box containing proteins, TFE3, E2F, ATF1, ATF2, ATF3, ATF4, ZF5, NFAT, CREB, HNF-4, C/EBP, SP1, CCAAT-box binding proteins, interferon regulation factor (IRF-1), Wilms tumor protein, ETS-binding protein, STAT, GATA-box binding proteins, e.g., GATA-3, and the forkhead family of winged helix proteins.
  • Other useful gene products include, carbamoyl synthetase I, ornithine
  • transcarbamylase arginosuccinate synthetase, arginosuccinate lyase, arginase,
  • fumarylacetacetate hydrolase phenylalanine hydroxylase, alpha- 1 antitrypsin, glucose-6- phosphatase, porphobilinogen deaminase, cystathione beta-synthase, branched chain ketoacid decarboxylase, albumin, isovaleryl-coA dehydrogenase, propionyl CoA carboxylase, methyl malonyl CoA mutase, glutaryl CoA dehydrogenase, insulin, beta- glucosidase, pyruvate carboxylate, hepatic phosphorylase, phosphorylase kinase, glycine decarboxylase, H-protein, T-protein, a cystic fibrosis transmembrane regulator (CFT ) sequence, and a dystrophin cDNA sequence.
  • CFT cystic fibrosis transmembrane regulator
  • Still other useful gene products include enzymes such as may be useful in enzyme replacement therapy, which is useful in a variety of conditions resulting from deficient activity of enzyme.
  • enzymes that contain mannose-6-phosphate may be utilized in therapies for lysosomal storage diseases (e.g., a suitable gene includes that encoding ⁇ -glucuronidase (GUSB)).
  • Still other useful gene products include those used for treatment of hemophilia, including hemophilia B (including Factor IX) and hemophilia A (including Factor VIII and its variants, such as the light chain and heavy chain of the heterodimer and the B-deleted domain; US Patent 6,200,560 and US Patent 6,221 ,349).
  • the present invention is not limited to any specific Factor VIII sequence.
  • Many natural and recombinant forms of Factor VIII have been isolated and generated. Examples of naturally occurring and recombinant forms of Factor VII can be found in the patent and scientific literature including, US Patent No.
  • non-naturally occurring gene sequences include antisense molecules and catalytic nucleic acids, such as ribozymes, which could be used to reduce overexpression of a target.
  • "Knockdown gene therapy” is directed towards a gene product which is associated with a disease or conditions in which the targeted gene is overexpressed, but which is not entirely extinguished by the therapy. Molecules such as microR A and small interfering RNA (siR A) may be delivered to accomplish knock out or knock down.
  • Target polypeptides include those polypeptides which are produced exclusively or at higher levels in hyperproliferative cells as compared to normal cells.
  • Target antigens include polypeptides encoded by oncogenes such as myb, myc, fyn, and the translocation gene bcr/abl, ras, src, P53, neu, trk and EGRF.
  • target polypeptides for anti-cancer treatments and protective regimens include variable regions of antibodies made by B cell lymphomas and variable regions of T cell receptors of T cell lymphomas which, in some embodiments, are also used as target antigens for autoimmune disease.
  • Other tumor associated polypeptides can be used as target polypeptides such as polypeptides which are found at higher levels in tumor cells including the polypeptide recognized by monoclonal antibody 17 1 A and folate binding polypeptides.
  • T cell mediated autoimmune diseases include Rheumatoid arthritis (RA), multiple sclerosis (MS), Sjogren's syndrome, sarcoidosis, insulin dependent diabetes mellitus (IDDM), autoimmune thyroiditis, reactive arthritis, ankylosing spondylitis, scleroderma, polymyositis, dermatomyositis, psoriasis, vasculitis, Wegener's granulomatosis, Crohn's disease and ulcerative colitis.
  • RA Rheumatoid arthritis
  • MS multiple sclerosis
  • Sjogren's syndrome sarcoidosis
  • IDDM insulin dependent diabetes mellitus
  • autoimmune thyroiditis reactive arthritis
  • ankylosing spondylitis scleroderma
  • polymyositis dermatomyositis
  • psoriasis psoriasis
  • vasculitis Wegener's granulomatosis
  • suitable therapeutic polypeptides and protein include those useful for treating individuals suffering from a rare disease.
  • rare disease include, e.g., myeloma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, cystic hematoma, cystic hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma, hematoma
  • Dysplasia Polyostotic, Fox-Fordyce Disease, Friedreich Ataxia, Fusobacterium, Gardner Syndrome, Gaucher Disease, Gerstmann Syndrome, Giant Lymph Node Hyperplasia, Glycogen Storage Disease Type I, Glycogen Storage Disease Type II, Glycogen Storage Disease Type IV, Glycogen Storage Disease Type V, Glycogen Storage Disease Type VII, Goldenhar Syndrome, Guillain-Barre Syndrome, Hallermann's Syndrome, Hamartoma Syndrome, Multiple Hartnup Disease, Hepatolenticular Degeneration, Hepatolenticular Degeneration, Hereditary Sensory and Motor Neuropathy Hirschsprung Disease, Histiocytic Necrotizing Lymphadenitis, Histiocytosis, Langerhans-Cell Hodgkin Disease, Horner Syndrome, Huntington Disease, Hyperaldosteronism, Hyperostosis, Diffuse Idiopathic Skeletal, Hypopituitarism, Inappropriate ADH Syndrome, Intestinal Polyps
  • Mucopolysaccharidosis I Mucopolysaccharidosis II, Mucopolysaccharidosis III, Mucopolysaccharidosis IV, Mucopolysaccharidosis VI, Multiple Endocrine Neoplasia Type 1, Munchausen Syndrome by Proxy, Muscular Atrophy, Spinal Neuroaxonal Dystrophies, Neuromyelitis Optica, Neuronal Ceroid-Lipofuscinoses, Niemann-Pick Diseases, Noonan Syndrome, Optic Atrophies, Hereditary Osteitis Deformans, Osteochondritis,
  • Sandhoff Disease Sarcoma, Ewing's, Sjogren's Syndrome, Sjogren-Larsson Syndrome, Smith-Lemli-Opitz Syndrome, Spinal Muscular Atrophies of Childhood, Sturge- Weber Syndrome, Sweating, Gustatory, Takayasu Arteritis, Tangier Disease, Tay-Sachs Disease, Thromboangiitis Obliterans, Thyroiditis, Autoimmune, Tietze's Syndrome, Togaviridae Infections, Tolosa-Hunt Syndrome, Tourette Syndrome, Uveomeningoencephalitic Syndrome Waardenburg's Syndrome, Wegener Granulomatosis, Weil Disease, Werner Syndrome, Williams Syndrome, Wilms Tumor, Wolff-Parkinson- White Syndrome, Wolfram Syndrome, Wolman Disease, Zellweger Syndrome, Zollinger-Ellison Syndrome, and von Willebrand Diseases.
  • the nucleotide sequence encoding of any of a number of immunogenic transgenes may be selected for codon modification to enhance tissue-preferential expression as described herein.
  • suitable immunogenic transgenes include those selected from a variety of viral families.
  • Example of desirable viral families against which an immune response would be desirable include, the picornavirus family, which includes the genera rhinoviruses, which are responsible for about 50% of cases of the common cold; the genera enteroviruses, which include polioviruses, coxsackieviruses, echoviruses, and human enteroviruses such as hepatitis A virus; and the genera apthoviruses, which are responsible for foot and mouth diseases, primarily in non-human animals.
  • target antigens include the VP1, VP2, VP3, VP4, and VPG.
  • Other viral families include the astroviruses and the calcivirus family.
  • the calcivirus family encompasses the Norwalk group of viruses, which are an important causative agent of epidemic gastroenteritis.
  • Still another viral family desirable for use in targeting antigens for inducing immune responses in humans and non-human animals is the togavirus family, which includes the genera alphavirus, which include Sindbis viruses, oss iver virus, and Venezuelan, Eastern & Western Equine encephalitis, and rubivirus, including Rubella virus.
  • the flaviviridae family includes dengue, yellow fever, Japanese encephalitis, St.
  • target antigens may be generated from the Hepatitis C or the coronavirus family, which includes a number of non-human viruses such as infectious bronchitis virus (poultry), porcine transmissible gastroenteric virus (pig), porcine hemagglutinatin encephalomyelitis virus (pig), feline infectious peritonitis virus (cats), feline enteric coronavirus (cat), canine coronavirus (dog), and human respiratory coronaviruses, which may cause the common cold and/or non A, B or C hepatitis, and which include the putative cause of sudden acute respiratory syndrome (SARS).
  • infectious bronchitis virus proultry
  • porcine transmissible gastroenteric virus pig
  • porcine hemagglutinatin encephalomyelitis virus pig
  • feline infectious peritonitis virus cats
  • feline enteric coronavirus cat
  • canine coronavirus dog
  • human respiratory coronaviruses which may cause the common cold and
  • target antigens include the El (also called M or matrix protein), E2 (also called S or Spike protein), E3 (also called HE or hemagglutin elterose) glycoprotein (not present in all coronaviruses), or N (nucleocapsid). Still other antigens may be targeted against the arterivirus family and the rhabdovirus family.
  • the rhabdovirus family includes the genera vesiculovirus (e.g., Vesicular Stomatitis Virus), and the general lyssavirus (e.g., rabies). Within the rhabdovirus family, suitable antigens may be derived from the G protein or the N protein.
  • the family filoviridae which includes hemorrhagic fever viruses such as Marburg and Ebola virus may be a suitable source of antigens.
  • the paramyxovirus family includes parainfluenza Virus Type 1 , parainfluenza Virus Type 3, bovine parainfluenza Virus Type 3, rubulavirus (mumps virus, parainfluenza Virus Type 2, parainfluenza virus Type 4, Newcastle disease virus (chickens), rinderpest, morbillivirus, which includes measles and canine distemper, and pneumovirus, which includes respiratory syncytial virus.
  • the influenza virus is classified within the family orthomyxovirus and is a suitable source of antigen (e.g., the HA protein, the Nl protein).
  • the bunyavirus family includes the genera bunyavirus (California encephalitis, La Crosse), phlebovirus (Rift Valley Fever), hantavirus (puremala is a hemahagin fever virus), nairovirus (Nairobi sheep disease) and various unassigned bungaviruses.
  • the arenavirus family provides a source of antigens against LCM and Lassa fever virus. Another source of antigens is the bornavirus family.
  • the reovirus family includes the genera reovirus, rotavirus (which causes acute gastroenteritis in children), orbiviruses, and cultivirus (Colorado Tick fever, Lebombo (humans), equine encephalosis, blue tongue).
  • the retrovirus family includes the sub family oncorivirinal which encompasses such human and veterinary diseases as feline leukemia virus, HTLVI and HTLVII, lentivirinal (which includes HIV, simian immunodeficiency virus, feline immunodeficiency virus, equine infectious anemia virus, and spumavirinal).
  • the papovavirus family includes the sub-family polyomaviruses (BKU and JCU viruses) and the sub family papillomavirus (associated with cancers or malignant progression of papilloma).
  • the adenovirus family includes viruses (EX, AD7, A D, O.B.) which cause respiratory disease and/or enteritis.
  • chordopoxvirinae which encompasses the genera orthopoxvirus (Variola major (Smallpox) and Vaccinia (Cowpox)), parapoxvirus, avipoxvirus, capripoxvirus, leporipoxvirus, suipoxvirus, and the sub family entomopoxvirinae.
  • the hepadnavirus family includes the Hepatitis B virus.
  • One unclassified virus which may be suitable source of antigens is the Hepatitis delta virus, Hepatitis E virus, and prions.
  • Another virus which is a source of antigens is Nipan Virus.
  • Still other viral sources may include avian infectious bursal disease virus and porcine respiratory and reproductive syndrome virus.
  • the alphavirus family includes equine arteritis virus and various Encephalitis viruses.
  • the present invention may also encompass immunogens which are useful to immunize a human or non-human animal against other pathogens including bacteria, fungi, parasitic microorganisms or multicellular parasites which infect human and non-human vertebrates, or from a cancer cell or tumor cell.
  • pathogens include pathogenic gram positive cocci include pneumococci; staphylococci (and the toxins produced thereby, e.g., enterotoxin B); and streptococci.
  • Pathogenic gram negative cocci include meningococcus; gonococcus.
  • Pathogenic enteric gram negative bacilli include enterobacteriaceae; pseudomonas, acinetobacteria and eikenella; melioidosis; salmonella; shigella; haemophilus; moraxella; H.
  • ducreyi which causes chancroid
  • brucella species brucellosis
  • Francisella tularensis which causes tularemia
  • Yersinia pestis plague
  • other yersinia pasteurella
  • streptobacillus moniliformis and spirillum Gram-positive bacilli include listeria monocytogenes; erysipelothrix rhusiopathiae; Corynebacterium diphtheria (diphtheria); cholera; B. anthracis (anthrax); donovanosis (granuloma inguinale); and bartonellosis.
  • Pathogenic anaerobic bacteria Diseases caused by pathogenic anaerobic bacteria include tetanus; botulism (Clostridum botulinum and its toxin); Clostridium perfringens and its epsilon toxin; other Clostridia; tuberculosis; leprosy; and other mycobacteria.
  • Pathogenic spirochetal diseases include syphilis; treponematoses: yaws, pinta and endemic syphilis; and leptospirosis.
  • infections caused by higher pathogen bacteria and pathogenic fungi include glanders (Burkholderia mallei); actinomycosis; nocardiosis; cryptococcosis, blastomycosis, histoplasmosis and coccidioidomycosis; candidiasis, aspergillosis, and mucormycosis; sporotrichosis; paracoccidiodomycosis, petriellidiosis, torulopsosis, mycetoma and chromomycosis; and dermatophytosis.
  • Rickettsial infections include Typhus fever, Rocky Mountain spotted fever, Q fever (Coxiella burnetti), and Rickettsialpox. Examples of mycoplasma and chlamydial infections include: mycoplasma pneumoniae;
  • Pathogenic eukaryotes encompass pathogenic protozoans and helminths and infections produced thereby include: amebiasis; malaria; leishmaniasis; trypanosomiasis; toxoplasmosis; Pneumocystis carinii; Trichans; Toxoplasma gondii; babesiosis; giardiasis; trichinosis; filariasis;
  • viral vectors and other constructs described herein are useful to deliver antigens from these organisms, viruses, their toxins or other by-products, which will prevent and/or treat infection or other adverse reactions with these biological agents.
  • the vectors of the invention can be used to deliver immunogens.
  • RA rheumatoid arthritis
  • TCRs T-cell receptors
  • These TCRs include V 3, V 14, and V 17.
  • RA rheumatoid arthritis
  • MS multiple sclerosis
  • TCRs include V 7 and V 10.
  • delivery of a nucleic acid sequence that encodes at least one of these polypeptides will elicit an immune response that will target T cells involved in MS.
  • TCRs In scleroderma, several specific variable regions of TCRs which are involved in the disease have been characterized. These TCRs include V 6, V 8, V 14, V 3 C, V 7, V 14, V 15, V 16, V 28 and V 12. Thus, delivery of a nucleic acid molecule that encodes at least one of these polypeptides will elicit an immune response that will target T cells involved in scleroderma.
  • an "anti-pathogen construct” which is a protein, peptide, or other molecule encoded by a nucleic acid sequence carried on a viral vector as described herein, which is capable of providing passive immunity against the selected pathogenic agent or a cross-reactive strain of the pathogenic agent.
  • the anti-pathogen construct is a neutralizing antibody construct against the pathogenic agent, e.g., a virus, bacterium, fungus, or a pathogenic toxin of said agent (e.g., anthrax toxin). Examples of such pathogens are provided herein.
  • a “neutralizing antibody” is an antibody which defends a cell from an antigen or infectious body by inhibiting or neutralizing its biological effect.
  • neutralizes and grammatical variations thereof, refer to an activity of an antibody that prevents entry or translocation of the pathogen into the cytoplasm of a cell susceptible to infection.
  • a neutralizing antibody is an antibody which defends a cell from an antigen or infectious body by inhibiting or neutralizing its
  • neutralizing antibody construct includes a full-length antibody (an immunoglobulin molecule), as well as antibody fragments or artificial constructs which have the ability to inhibit or neutralize an antigen or infectious agent. These antibody fragments or artificial constructs may include a single chain antibody, a Fab fragment, a univalent antibody, or an immunoadhesin.
  • the neutralizing antibody construct may be a monoclonal antibody, a "humanized” antibody, a polyclonal antibody, or another suitable construct.
  • immunoglobulin molecule is a protein containing the immunologically-active portions of an immunoglobulin heavy chain and immunoglobulin light chain covalently coupled together and capable of specifically combining with an antigen.
  • Immunoglobulin molecules are of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., IgGl , IgG2, IgG3, IgG4, IgAl and IgA2) or subclass.
  • antibody and “immunoglobulin” may be used interchangeably herein.
  • immunoglobulin heavy chain is a polypeptide that contains at least a portion of the antigen binding domain of an immunoglobulin and at least a portion of a variable region of an immunoglobulin heavy chain or at least a portion of a constant region of an immunoglobulin heavy chain.
  • the immunoglobulin derived heavy chain has significant regions of amino acid sequence homology with a member of the immunoglobulin gene superfamily.
  • the heavy chain in a Fab fragment is an immunoglobulin- derived heavy chain.
  • an “immunoglobulin light chain” is a polypeptide that contains at least a portion of the antigen binding domain of an immunoglobulin and at least a portion of the variable region or at least a portion of a constant region of an immunoglobulin light chain.
  • the immunoglobulin-derived light chain has significant regions of amino acid homology with a member of the immunoglobulin gene superfamily.
  • An “immunoadhesin” is a chimeric, antibody-like molecule that combines the functional domain of a binding protein, usually a receptor, ligand, or cell-adhesion molecule, with immunoglobulin constant domains, usually including the hinge and Fc regions.
  • a “"fragment antigen-binding" (Fab) fragment” is a region on an antibody that binds to antigens. It is composed of one constant and one variable domain of each of the heavy and the light chain.
  • a fragment of an immunoglobulin coding sequence may be modified according to the methods described herein. Suitable fragments may include the coding region for one or more of, e.g., a heavy chain, a light chain, and/or fragments thereof such as the constant region of a heavy chain (CHI , CH2 and/or CH3) and/or or the constant region of a light chain.
  • variable regions of a heavy chain or light chain may be modified. Examples of such fragments include, without limitation: Position (nt)
  • VH variable region heavy chain
  • CHI constant region 1 heavy chain
  • Still other immunoglobulin coding regions may be modified.
  • the expression cassette can be carried on any suitable vector, e.g., a plasmid, which is delivered to a viral vector (e.g., a recombinant (r) AAV).
  • a viral vector e.g., a recombinant (r) AAV
  • the expression cassette can be carried on any suitable vector, e.g., a plasmid, which is delivered to a viral vector (e.g., a recombinant (r) AAV).
  • Suitable regulatory sequences refer to nucleotide sequences located upstream (5' non-coding sequences), within, or downstream (3' non-coding sequences) of a coding sequence, and which influence the transcription, RNA processing or stability, or translation of the associated coding sequence. Regulatory sequences may include promoters, translation leader sequences, introns, polyadenylation recognition sequences, RNA
  • transgenes include, but are not limited to chicken ⁇ -actin (CB) promoter, human
  • CMV cytomegalovirus
  • SV40 simian virus 40
  • U6 simian virus 40
  • metallothionein promoters EFla promoter
  • EFla ubiquitin promoter
  • HPRT hypoxanthine phosphoribosyl transferase
  • DHFR dihydrofolate reductase
  • phosphoglycerol mutase promoter the ⁇ -actin promoter (Lai et al., Proc. Natl. Acad. Sci.
  • LTR long terminal repeats
  • thymidine kinase promoter of Herpes Simplex Virus and other constitutive promoters known to those of skill in the art.
  • tissue- or cell- preferential promoters suitable for use in the present invention include, but are not limited to, endothelin-I (ET -I) and Flt-I, which are for endothelial cells, FoxJl (that targets ciliated cells), human thyroxine binding globulin (TBG) and alpha- 1 anti -trypsin (A1AT) for liver, troponin and T (TnT) for heart, clara cell 10 (CC10), surfactant protein C (SPC) and FoxJl for heart; synapsin, tyrosine hydroxylase, CaMKII (Ca2+/calmodulin-dependent protein kinase) for central nervous system/brain, insulin and elastase-I for pancrease, Ap2 and adiponector for adipocyte, desmin and MHC for muscle, and VMD for retina. Still others are known in the art.
  • Inducible promoters suitable for controlling expression of the transgene include promoters responsive to exogenous agents (e.g., pharmacological agents) or to physiological cues.
  • These response elements include, but are not limited to a hypoxia response element (HRE) that binds HIF-Ia and ⁇ , a metal-ion response element such as described by Mayo et al. (1982, Cell 29:99-108); Brinster et al. (1982, Nature 296:39-42) and Searle et al. (1985, Mol. Cell. Biol. 5:1480-1489); or a heat shock response element such as described by Nouer et al. (in: Heat Shock Response, ed. Nouer, L., CRC, Boca Raton, Fla., ppI67-220, 1991).
  • HRE hypoxia response element
  • regulatable promoters which are ligand-dependent transcription factor complexes that may be used in the invention include, without limitation, members of the nuclear receptor superfamily activated by their respective ligands (e.g., glucocorticoid, estrogen, progestin, retinoid, ecdysone, and analogs and mimetics thereof) and rTTA activated by tetracycline.
  • the gene switch is an EcR-based gene switch. Examples of such systems include, without limitation, the systems described in US Patent Nos. 6,258,603, 7,045,315, U.S. Published Patent Application Nos.
  • WO 02/066612 WO 02/066613, WO 02/066614, WO 02/066615, WO 02/29075, and WO 2005/108617, each of which is incorporated by reference in its entirety.
  • An example of a non-steroidal ecdysone agonist-regulated system is the RheoSwitch® Mammalian Inducible Expression System (New England Biolabs, Ipswich, MA).
  • Still other promoter systems may include response elements including but not limited to a tetracycline (tet) response element (such as described by Gossen & Bujard (1992, Proc. Natl. Acad. Sci. USA 89:5547-551); or a hormone response element such as described by Lee et al. (1981, Nature 294:228-232); Hynes et al. (1981, Proc. Natl. Acad. Sci. USA 78:2038-2042); Klock et al. (1987, Nature 329:734-736); and Israel & Kaufman (1989, Nucl. Acids Res. 17:2589-2604) and other inducible promoters known in the art.
  • tetracycline response element such as described by Gossen & Bujard (1992, Proc. Natl. Acad. Sci. USA 89:5547-551
  • a hormone response element such as described by Lee et al. (1981, Nature 294:228-232); Hy
  • expression of the neutralizing antibody construct can be controlled, for example, by the Tet-on/off system (Gossen et al., 1995, Science 268:1766-9; Gossen et al., 1992, Proc. Natl. Acad. Sci. USA., 89(12):5547-51); the TetR-KRAB system (Urrutia R., 2003, Genome Biol., 4(10):231 ; Deuschle U et al., 1995, Mol Cell Biol. (4):1907-14); the mifepristone (RU486) regulatable system (Geneswitch; Wang Y et al., 1994, Proc. Natl. Acad. Sci. USA., 91 (17):8180-4; Schillinger et al., 2005, Proc. Natl. Acad. Sci. U S
  • a gene switch is based on heterodimerization of FK506 binding protein (FKBP) with FKBP rapamycin associated protein (FRAP) and is regulated through rapamycin or its non-immunosuppressive analogs.
  • FKBP FK506 binding protein
  • FRAP FKBP rapamycin associated protein
  • ARGENTTM Transcriptional Technology ARIAD Pharmaceuticals, Cambridge, Mass.
  • rapalogs Transcription Plasmid Kit, Version 2.0 (9109/02), each of which is incorporated herein by reference in its entirety.
  • the Ariad system is designed to be induced by rapamycin and analogs thereof referred to as "rapalogs". Examples of suitable rapamycins are provided in the documents listed above in connection with the description of the ARGENTTM system.
  • the molecule is rapamycin [e.g., marketed as apamuneTM by Pfizer].
  • a rapalog known as AP21967 [ARIAD] is used.
  • rapalogs include, but are not limited to such as AP26113 (Ariad), AP1510 (Amara, J.F., et al.,1997, Proc Natl Acad Sci USA, 94(20): 10618-23) AP22660, AP22594, AP21370, AP22594, AP23054, AP1855, AP1856, AP1701, AP1861, AP1692 and AP1889, with designed 'bumps' that minimize interactions with endogenous FKBP. Still other rapalogs may be selected, e.g., AP23573 [Merck].
  • the vector may also include conventional control elements which are operably linked to the coding sequence in a manner which permits transcription, translation and/or expression of the encoded product (e.g., a neutralizing antibody or a portion thereof) in a cell transfected with the plasmid vector or infected with the virus produced by the invention.
  • operably linked sequences include both expression control sequences that are contiguous with the gene of interest and expression control sequences that act in trans or at a distance to control the gene of interest.
  • heterologous when used with reference to a protein or a nucleic acid indicates that the protein or the nucleic acid comprises two or more sequences or subsequences which are not found in the same relationship to each other in nature.
  • the nucleic acid is typically recombinantly produced, having two or more sequences from unrelated genes arranged to make a new functional nucleic acid.
  • the nucleic acid has a promoter from one gene arranged to direct the expression of a coding sequence from a different gene.
  • the promoter is heterologous.
  • An adeno-associated virus (AAV) viral vector is an AAV DNase-resistant particle having an AAV protein capsid into which is packaged nucleic acid sequences for delivery to target cells.
  • the AAV sequences on the expression cassette comprise only minimal AAV sequences to avoid the risk of replication.
  • the minimal AAV sequences include the AAV inverted terminal repeat sequences (ITR).
  • the 5' ITR and the 3' ITR are the minimal AAV sequences required in cis in order to express a transgene encoded by a nucleic acid sequence packaged in the AAV capsid.
  • the ITRs flank the modified coding sequence for a selected gene product.
  • the AAV vector contains AAV 5' and 3' ITRs, which may be of the same AAV origin as the capsid, or which may be of a different AAV origin (to produce an AAV pseudotype).
  • the coding sequences for the replication (rep) and/or capsid (cap) are removed from the AAV genome and supplied in trans or by a packaging cell line in order to generate the AAV vector.
  • An AAV capsid is composed of 60 capsid protein subunits, VP1, VP2, and VP3, that are arranged in an icosahedral symmetry in a ratio of approximately 1 :1 :10 to 1 : 1 :20, depending upon the selected AAV.
  • the capsid type does play a role in tissue specificity.
  • the sequences of a variety of AAV have been described, as have methods of generating vectors having the AAV capsids.
  • an AAV cap for use in the viral vector can be generated by mutagenesis (i.e., by insertions, deletions, or substitutions) of one of the aforementioned AAV Caps or its encoding nucleic acid.
  • the AAV capsid is chimeric, comprising domains from two or three or four or more of the aforementioned AAV capsid proteins.
  • the AAV capsid is a mosaic of Vpl, Vp2, and Vp3 monomers from two or three different AAVs or recombinant AAVs.
  • an rAAV composition comprises more than one of the aforementioned Caps.
  • the IT s are the only AAV components required in cis in the same construct as the transgene.
  • the cap and rep genes can be supplied in trans. Accordingly, DNA constructs can be designed so that the AAV ITRs flank the coding sequence, thus defining the region to be amplified and packaged - the only design constraint being the upper limit of the size of the DNA to be packaged (approximately 4.5 kb).
  • Adeno-associated virus engineering and design choices that can be used to save space are known in the art.
  • the components required to be cultured in the host cell to package an AAV minigene in an AAV capsid may be provided to the host cell in trans.
  • any one or more of the required components ⁇ e.g., minigene, rep sequences, cap sequences, and/or helper functions
  • a stable host cell which has been engineered to contain one or more of the required components using methods known to those of skill in the art.
  • a stable host cell will contain the required component(s) under the control of an inducible promoter.
  • the required component(s) may be under the control of a constitutive promoter. Examples of suitable inducible and constitutive promoters are provided herein, in the discussion of regulatory elements suitable for use with the transgene.
  • a selected stable host cell may contain selected component(s) under the control of a constitutive promoter and other selected component(s) under the control of one or more inducible promoters.
  • a stable host cell may be generated which is derived from 293 cells (which contain El helper functions under the control of a constitutive promoter), but which contains the rep and/or cap proteins under the control of inducible promoters. Still other stable host cells may be generated by one of skill in the art.
  • the minigene, rep sequences, cap sequences, and helper functions required for producing the rAAV of the invention may be delivered to the packaging host cell in the form of any genetic element which transfer the sequences carried thereon.
  • the selected genetic element may be delivered by any suitable method, including those described herein.
  • the methods used to construct any embodiment of this invention are known to those with skill in nucleic acid manipulation and include genetic engineering, recombinant engineering, and synthetic techniques. See, e.g., Sambrook et al, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor, NY.
  • methods of generating rAAV virions are well known and the selection of a suitable method is not a limitation on the present invention. See, e.g., K. Fisher et al, (1993) J. Virol, 70:520-532 and US Patent No. 5,478,745.
  • the AAV IT s, and other selected AAV components described herein may be readily selected from among any AAV.
  • more than one AAV source may provide elements to an AAV vector.
  • a pseudotyped AAV may contain ITRs from a source which differs from the source of the AAV capsid.
  • a chimeric AAV capsid may be utilized.
  • Still other AAV components may be selected. Sources of such AAV sequences are described herein and may also be isolated or obtained from academic, commercial, or public sources ⁇ e.g., the American Type Culture Collection, Manassas, VA).
  • the AAV sequences may be obtained through synthetic or other suitable means by reference to published sequences such as are available in the literature or in databases such as, e.g., GenBank®, PubMed®, or the like.
  • the pharmaceutical compositions include a single vector containing an expression cassette comprising a modified ORF as described above.
  • the composition includes more than one vector, each containing one or more expression cassettes.
  • Each expression cassette comprises a modified ORF.
  • the composition includes multiple viral vectors, each containing one or more expression cassettes as described herein.
  • the AAV vectors may be suspended in a physiologically compatible carrier for administration to a human or non-human mammalian patient.
  • Suitable carriers may be readily selected by one of skill in the art in view of the route of delivery.
  • one suitable carrier includes saline, which may be formulated with a variety of buffering solutions ⁇ e.g., phosphate buffered saline).
  • Other exemplary carriers include sterile saline, lactose, sucrose, calcium phosphate, gelatin, dextran, agar, pectin, peanut oil, sesame oil, and water. The selection of the carrier is not a limitation of the present invention.
  • compositions of the invention may contain, in addition to the rAAV and carrier(s), other conventional pharmaceutical ingredients, such as preservatives, or chemical stabilizers.
  • suitable exemplary preservatives include chlorobutanol, potassium sorbate, sorbic acid, sulfur dioxide, propyl gallate, the parabens, ethyl vanillin, glycerin, phenol, and
  • Suitable chemical stabilizers include gelatin and albumin.
  • the following Table 18 provides a comparison of the identity of the modified ORFs generated and studied herein.
  • the sequences of the ORFs are contained in SEQ ID NOs: 1 - 12 and 30. An alignment of the sequences is provided in Figs. lA-1 J.
  • ORFs were engineered into a plasmid construct (F2A) and expression levels were assessed in HEK 293 cells.
  • the sequences of these plasmids are provided in the attached FIG. 5 (SEQ ID NOs: 13-29), which is incorporated by reference herein.
  • the data in Table 19 provides the results on an in vitro assessment of the plasmid constructs in HEK 293 cells.
  • CMV human cytomegalovirus promoter
  • PI commercially available enhancer
  • F2A is a plasmid containing the "base” or parental anti-HIV antibody ORF under the control of the CMV-IE promoter.
  • Mini-C is similar to the F2a, in that it contains the "base” or parental anti-HIV antibody ORF under the control of the CMV-IE promoter, but it further contains a 5 'UTR.
  • ORF26, IA U and IAM U constructs showing the strongest expression levels. There were also significant differences in in vitro expression levels for all modified genes expressed under the CMV promoter with the enhancer (CMV-IE). These data show that none of the modified constructs provide expression levels significantly higher than the base vector. With the promoter-enhancer, ORF 35 show the strongest expression levels followed by ORFl 1.
  • the plasmids carrying the genes described above expressed under the CMV-PI promoter/enhancer were packaged into AAV8 capsids using published methods and the resulting AAV.CMV-lE.modified genes were expressed in a non-secretory tissue (muscle) and a secretory tissue (lung). Except where otherwise specified, animals (RAG KO) were delivered 2 x 10 10 genomic particles/mL. For those animals injected im, serum levels of protein were determined on day 50 post-injection by ELISA (Fig. 2 (middle bars)). For those animals for which the constructs were delivered by nasal installation, protein levels in bronchial lavage were determined by ELISA seven days following installation. Table 20 provides the results. Table 20
  • the tested constructs outperformed the vector expressing the parental gene in muscle.
  • the muscle expression levels observed for the ORF 1 vector was about the same as for the vector carrying the parental gene, but at half the dose.
  • the highest expression levels for muscle were observed for ORF35 and ORF39, which were both approximately four times the expression level of the parental gene.
  • the expression levels observed for vector carrying the parental gene were higher than those for the vectors carrying the other modified genes. Significant variations in expression levels were observed, with the vectors carrying IA U, ORF40 and ORF2 expressing at higher levels that the other vectors with the exception of the vector carrying the parental gene.
  • FIG. 6 is a graph showing the expression of the 201 construct in muscle (bottom line) and liver (top line) of mice versus time post transduction. 5 mice per group were injected at the indicated dosages (lxl O 10 or lxl O 11 GC/per mouse). Concentrations were determined by ELISA. Capture accomplished 10 by binding to SIV mac251 gpl20; detection by Fc chain antibody (IgGl) conjugated with
  • FIG. 7 is a graph showing the expression of the 10A construct in muscle (bottom line) and liver (top line) of mice versus time post transduction. 5 mice per group were injected at the dosage of lxl O 11 GC/per mouse. CMV promoter was used for IM injections; 15 TBG promoter was used for IV injections.
  • the 3bncl 17 antibody coding sequence was optimized using the codon frequency of human (Table 2) or 201 (Table 16) manually.
  • the codon frequencies for the final sequences are shown in tables 22 (human) and 23 (201) below.
  • AAV8 constructs utilizing the TBM promoter and incorporating 3bnCl 17/hum (SEQ ID NO: 34) or 3bnCl 17/201 (SEQ ID NO: 33) sequence were injected intravenously into mice at a dosage of lxlO 11 GC/per mouse. Expression in liver is shown in Fig. 8. Expression of the 3bnCl 17/201 in liver was -2.5 to over 3 times greater than expression using the human codon frequency optimized sequence.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Described herein are synonymously altered gene sequences which express protein in differing levels within secretory as compared to non-secretory target tissue. An expression cassette comprising an open reading frame (ORF) for a protein under the control of regulatory sequences which direct expression of the product in cell, which ORF has been modified to preferentially increase expression levels in a selected tissue, wherein the modified ORF is characterized by a triplet frequency of any one of Tables 3 - 12, 16 or 17.

Description

TISSUE PREFERENTIAL CODON MODIFIED EXPRESSION
CASSETTES, VECTORS CONTAINING SAME, AND USE
THEREOF STATEMENT OF GOVERNMENT INTEREST
This invention was made with government support under grant no. No. 64047- LS-DRP awarded by Defense Advanced Research Projects Agency. The government has certain rights in the invention.
BACKGROUND OF THE INVENTION Various therapies in gene therapy rely upon the expression of recombinant genes in heterologous systems. A variety of viral vectors have been described for delivery of immunogenic and therapeutic products to a host. One vector system which has been described in the literature as very attractive for long-term expression of a transgene product is a recombinant adeno-associated virus, due to its relatively low immunogenicity and the fact that it is not associated with any clinical sequelae in humans. Adeno-associated virus (AAV) is a small, non-enveloped human parvovirus that packages a linear strand of single stranded DNA genome that is 4.7 kb. The capsid of an AAV contains 60 copies (in total) of three viral proteins (VPs), VP1, VP2, and VP3, in a predicted ratio of 1 :1 : 10-20, arranged with T=l icosahedral symmetry [H-J Nam, et al., J Virol., 81(22): 12260-12271 (Nov 2007)]. The three VPs are translated from the same mRNA, with VP1 containing a unique N-terminal domain in addition to the entire VP2 sequence at its C-terminal region [Nam et al., cited above]. VP2 contains an extra N-terminal sequence in addition to VP3 at its C terminus.
Codon usage bias has been reported for numerous organisms, from viruses to eukaryotes. Since the genetic code is degenerate (i.e., each amino acid can be coded by on average three different codons), the DNA sequence can be modified by synonymous nucleotide substitutions without altering the amino acid sequence of the encoded protein. Such synonymous codon optimization has been performed for the purpose of optimizing expression in a desired host, as described in the scientific literature and in patent documents. See, US Patent Numbers 5,786,464 and 6,114,148. Much of the early work in this called optimization, focused on altering the rare codons in the target gene so that they more closely reflect the codon usage of the host without modifying the amino acid sequence of the encoded protein. Since the early published work in this area, a variety of different algorithms have been described for modifying coding sequences for expression in different bacterial and eukaryotic host cell species.
In 2004, Plotkin, et al, Proc Natl Acad Sci. USA, 1010:12588-12591 (2004) reported significant differences in synonymous codon usage between genes specifically expressed in different tissues. However, more recent work by Semon et al, Mol Biol Evol, 23(3):523-529 (2006) re-evaluated that work and concluded that variability of synonymous codon usage between tissues is much smaller than variability within tissues. Semon et al further report that the synonymous codon usage variability reported by Plotkin et al was due only to GC- content differences, which affects introns and intergenic regions as well as synonymous codon positions.
For a variety of reasons, including cost, efficiency, and safety, there remains a need in the art for vectors which expression higher levels of gene products in a target cell.
SUMMARY OF THE INVENTION
Expression cassettes and vectors containing a gene which is designed to enhance expression in a selected type of tissue are provided herein. In one aspect, the present invention provides a gene sequence which is designed to preferentially express in a non- secretory tissue {e.g., muscle). In another aspect, the present invention provides a gene which has codons designed to preferentially express in a secretory tissue {e.g., muscle, respiratory epithelium or liver). And in another aspect, codon frequency tables are described which can be used to design a gene sequence for other, unrelated gene products, for example FIX, LDLPv, unrelated antibodies, or any other therapeutic transgenes. to optimize tissue specific expression.
In a further aspect, the invention provides an AAV comprising a modified gene which has been designed to express in higher levels in muscle. In one example, the AAV has an AAV8 capsid. In another example, the modified gene is a modified antibody gene.
In still another aspect, the invention provides an AAV comprising a modified gene which has been codon optimized to express in higher levels in respiratory epithelium. In one example, the AAV has an AAV8 capsid. In another aspect, the invention provides an expression cassette comprising an open reading frame (ORF) under the control of regulatory sequences which direct expression of the product in a muscle cell, which ORF has been modified to preferentially increase expression levels in muscle, wherein the modified ORF haveWs a sequence selected from the group consisting of ORF1 (SEQ ID NO: 9), ORF26 (SEQ ID NO: 6), ORF 28 (SEQ ID NO: 5), ORF 30 (SEQ ID NO: 4), ORF35 (SEQ ID NO: 3), ORF39 (SEQ ID NO: 2), ORF40 (SEQ ID NO: 1), ORF42 (SEQ ID NO: 30), IA (SEQ ID NO: 10), 201 (SEQ ID NO: 31) and IAM (SEQ ID NO: 11). In one example, the modified ORF is selected from ORF35 and ORF39. In another example, the modified ORF is ORF40. In a further example, the modified ORF is selected from ORF26 and ORF30. In another example, the modified ORF is selected from ORF26, ORF35 and ORFIAU. In one embodiment, the expression cassette comprises a tissue preferential promoter. When designed for packaging into a recombinant AAV, the expression cassette may comprise AAV inverted terminal repeats (ITRs) flanking (i.e., both 3' and 5/upstream and downstream) of the coding sequence. Optionally, the ITRs are from a different source AAV than the AAV which provides the capsid. In another aspect, the invention provides an expression cassette comprising an open reading frame under the control of regulatory sequences which direct expression of the product in liver cells, where the ORF has been modified to preferentially increase expression levels in liver. Expression cassettes for directing expression in respiratory epithelium or other tissue are described.
In a further aspect, the invention provides a vector comprising the expression cassette described herein and other genetic elements. In one embodiment, the vector is a recombinant adeno-associated virus (AAV) having an AAV capsid in which the expression cassette is packaged.
In still a further aspect, the invention provides a recombinant AAV comprising an AAV8 capsid and an expression cassette for an anti-HIV antibody, wherein the expression cassette is adapted for expression in a selected target tissue, said expression cassette comprising a modified ORF having a sequence selected from the group consisting of ORF 1 (SEQ ID NO: 9), ORF26 (SEQ ID NO: 6), ORF 28 (SEQ ID NO: 5), ORF 30 (SEQ ID NO: 4), ORF35 (SEQ ID NO: 3), ORF39 (SEQ ID NO: 2), ORF40 (SEQ ID NO: 1), ORF42 (SEQ ID NO: 30), IA (SEQ ID NO: 10), 201 (SEQ ID NO: 31) and IAM (SEQ ID NO: 11).
In another aspect, the invention provides a pharmaceutical composition comprising one or more vectors, each containing one or more expression cassettes. Each expression cassette comprises a modified ORF. In one embodiment, the ORF is selected from ORF26 (SEQ ID NO: 6), ORF 28 (SEQ ID NO: 5), ORF 30 (SEQ ID NO: 4), O F35 (SEQ ID NO: 3), ORF39 (SEQ ID NO: 2), ORF40 (SEQ ID NO: 1), ORF42 (SEQ ID NO: 30), IA (SEQ ID NO: 10), IAM (SEQ ID NO: 11), and 201 (SEQ ID NO: 31).
Still other aspects and advantages will be apparent from the detailed description of the invention.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. lA-1 J is an alignment of the sequences of genes all encoding the same anti-HIV antibody protein construct. The gene constructs use different synonymous codons for the same amino acids and are aligned with the parental (base) gene sequences as a frame of reference.
FIG. 2 is a bar chart illustrating AAV-mediated expression of gene constructs modified according to 12 different schemas as compared to a base vector containing the original parental sequence. The codon frequencies used for those modifications are shown in the Tables 1-12, and the parent codon frequency is shown in Table 13. Table 14 shows the codon frequencies which are used in most mammalian codon optimization protocols.
Expression of the gene under the control of human cytomegalovirus promoter (CMV(first bar)) or a CMV promoter with a commercially available enhancer (Promega intron, PI)(third bar) were assessed in HEK 293 cells at 72 hours post-infection. These were compared to expression observed with the CMV-PI construct in RAG knock-out mice injected intramuscularly as described in the Example (middle bar).
FIG. 3 is a line graph illustrating AAV-mediated expression of 12 codon biased constructs.
FIG. 4 is a bar chart of the data illustrated in Fig. 2 presented in a different format. For muscle expression, n=3 mice; for bronchial lavage n=2 mice; for transfections, n=2 wells, in addition two independent transfections were performed on different days with similar outcome. Each "n" was assayed by ELISA in duplicate (serum for muscle expression and transfections at 4 different dilutions and bronchial lavage at 2 different dilutions) using protein A capture, and detected using biotinylated anti -human IgGl antibodies as primary, and streptavidin conjugated HRP as secondary. Affinity purified MAB was used as a standard to make 8 point calibration curve. Constructs were packaged into AAV8 vector using triple transfection production method in HEK293 cells and purified by tangential flow filtration followed by gradient centrifugation. Viral titer was determined by qPC . 2 x10 GC(genome copies)/mouse were administered intramuscularly in 30 μΐ injection into RAG KO mice. For bronchial lavage 8 x 1010 GC/mouse were administered by intranasal instillation in 50 μΐ into C57B16 mice. For IM injections, blood samples were collected weekly for 2 months via orbital bleeding, and serum was assayed by ELISA. For bronchial lavage, mice were sacrificed on day 7 after vector administration, and 1 ml of PBS was used to lavage the airways. Concentrations that are in the table are not recalculated for the mucosal surfaces, but rather are straight concentrations in the lavage sample. Transfections were done on 6 well plates using lipofectamine, using standard conditions with the recommended amount of the DNA as manufacturer suggests.
FIG. 5A-5AAA provides the sequences and features of the plasmid constructs used in Example 1 below.
FIG. 6 is a graph showing the expression of the 201 construct in muscle (bottom line) and liver (top line) of mice versus time post transduction. 5 mice per group were injected at the indicated dosages (lxlO10 GC/per mouse or lxlO11 GC/mouse). Concentrations were determined by ELISA. Capture accomplished by binding to SIV mac251 gpl20; detection by Fc chain antibody (IgGl) conjugated with biotin, followed by HRP-streptavidin.
FIG. 7 is a graph showing the expression of the 10A construct in muscle (bottom line) and liver (top line) of mice versus time post transduction. 5 mice per group were injected at the dosage of lxlO11 GC/per mouse. CMV promoter was used for IM injections; TBG promoter was used for IV injections.
FIG. 8 is a graph demonstrating the effect of variable codon usage on expression of 3bncl 17 in liver. The 3bncl 17 antibody coding sequence was optimized using the codon frequency of human (Table 2)(top line) or 201 (Table 16)(bottom line). Expression is shown as μg/mL serum. The TBG promoter construct was used at a dosage of lxlO11 GC/per mouse.
FIG. 9A provides the nucleic acid sequences of the 3bcnl 17 antibody following modification according to the 201 frequency table (Table 16).
FIG. 9B provides the nucleic acid sequences of the 3bcnl 17 antibody following modification according to the human frequency table (Table 2).
FIG. 10A provides the nucleic acid sequences of the 201 construct.
FIG. 10B provides the nucleic acid sequences of the 10A construct. DETAILED DESCRIPTION OF THE INVENTION
The present invention provides expression cassettes and vectors containing genes which are designed to enhance expression in a desired type of tissue. The present invention provides nucleic acid molecules and vectors carrying genes with codons which are designed for expression in various tissues (e.g., muscle, liver, respiratory epithelium, etc).
"Coding sequence" refers to a DNA sequence that encodes a specific amino acid sequence. An open reading frame (ORF) is a continuous sequence of DNA that contains a start codon, a subsequent region which usually has a length which is a multiple of 3 nucleotides, and a stop codon in the same reading frame.
Since the genetic code is degenerate (i.e., each amino acid can be coded by different codons), the DNA sequence can be modified by nucleotide substitutions without altering the amino acid sequence of the encoded protein. Such changes are referred to herein as synonymous codon modifications. Base combinations which encode some of the standard amino acids are provided below.
Codon Table 1
Figure imgf000007_0001
Figure imgf000008_0001
lysine TTT AAA 1 UUU
Figure imgf000009_0001
tyrosine ATA UAU 1 AUA
Figure imgf000010_0001
The term "codon usage bias" refers to differences in the frequency of occurrence of synonymous codons in coding DNA. A variety of statistical methods have been described to analyze codon frequency in the literature. Additionally, there are many computer programs available to implement these statistical analyses enumerated above, including CodonW, GCUA, INCA, etc. Methods of codon optimization for expression in a specific species have been described. For example, Table 2 provides a conventional codon frequency for Homo sapiens (human) as reported by the Codon Usage Database: http://www.kazusa.or.jp/codoii/. These codon frequency are reported as frequency of an mRNA triplet (codon) per thousand codons. Given a table of codon frequencies presented based on the mRNA sequence, the corresponding cDNA or tRNA triplets may be readily determined by one of skill in the art, e.g., using Table 1 above.
Ta ble 2
Sequence Codon (frequency: per thousand)
u u u 17.6 UCU 15.2 UAU 12.2 UG U 10.6 u uc 20.3 UCC 17.7 UAC 15.3 UGC 12.6
U UA 7.7 UCA 12.2 UAA 1 UGA 1.6
U UG 12.9 UCG 4.4 UAG 0.8 UGG 13.2
CU U 13.2 ecu 17.5 CAU 10.9 CGU 4.5 cue 19.6 CCC 19.8 CAC 15.1 CGC 10.4
CUA 7.2 CCA 16.9 CAA 12.3 CGA 6.2
CUG 39.6 CCG 6. CAG 34.2 CGG 11.4
AU U 16 ACU 13.1 AAU 17 AG U 12.1
AUC 20.8 ACC 18.9 AAC 19.1 AGC 19.5 AUA 7.5 ACA 15.1 AAA 24.4 AGA 12.2
AUG 22 ACG 6.1 AAG 31.9 AGG 12
G U U 11 GCU 18.4 GAU 21.8 GG U 10.8
G UC 14.5 GCC 27.7 GAC 25.1 GGC 22.2
G UA 7.1 GCA 15.8 GAA 29 GGA 16
G UG 28.1 GCG 7.4 GAG 39.6 GGG 16.5
As described in the examples below, a study was designed to test whether codons play a role in expression levels which can be achieved in different tissues. The results of this study shows that modified codons do not express at the same levels in all cell or tissue types within a species (e.g., humans).
Using the information provided herein (e.g„ in one or more of Table 3, Table 4, Table 5, Table 6, Table 7, Table 8, Table 9, Table 10, Table 11, Table 12, Table 16, and/or Table 17), one may design modified genes having codons which preferentially enhance expression levels in a selected target tissue. In one example, the target tissue is an organ, tissue, or cell type with natural secretory pathways, e.g., liver, lung, epithelial cells (e.g., lung, gastrointestinal, exocrine, etc), sebaceous glands, hormone secretory cells, tears (meibomiah glands), among others. The target tissue may be a secreting or non-secreting organ, tissue or cell type, e.g., skeletal muscle, brain, ocular photoreceptor cells, etc. In another example, the codons are selected for a more specific target, e.g., for skeletal muscle, or for respiratory epithelium, or liver. In one embodiment, the codons are optimized for a selected tissue or organ (e.g., muscle), using the triplet frequency shown in the analytic table for or05 (Table 6), or a frequency within about 10% thereof. In another embodiment, the codons are optimized for a target (e.g., muscle), using the triplet frequency shown in the analytic table for or09 (Table 5) or a frequency within 10% thereof. According to the invention, the nucleic acid sequence encoding the product is modified with synonymous codon sequences in a tissue-preferential manner. Suitably, the entire length of the open reading frame (ORF) for the product is modified. However, in some embodiments, only a fragment of the ORF may be altered.
In one embodiment, the codons are generated based on the codon frequency of a selected table, or a frequency within about 10%, within about 5%, within about 3%, or within about 1% of the codon frequency of any one of the Tables provided herein. As used herein, "within about 10% frequency" may encompass the frequency of codons for a selected amino acid (e.g., Ala) within a selected Table, or the codon frequencies within a selected Table may be within 10% for each represented amino acid within a selected Table. For example, computer programs currently exist (e.g., Vector NTI® (Life Technologies)) and/or may be readily designed, which allow importation or use of a codon frequency such as that of any of the tables provided herein and the backtranslation of a nucleic acid sequence (e.g., mR A or cDNA). The resulting sequence may be synthesized or modified using genetic engineering techniques.
By utilizing a codon frequency selected from one or more of the Tables 3-12, 16, 17, or a frequency within about 10% thereof (or optionally Table 13, 14 or 15), one can apply the codon frequencies to a selected polypeptide sequence, and produce a nucleic acid fragment of a codon-optimized coding region which encodes the polypeptide, but which uses codons more optimal for a given tissue. Suitably, the entire length of the open reading frame (ORF) for the product is modified. However, in some embodiments, only a fragment of the O F may be altered. By using one of these methods, one can apply the frequencies to any given protein, enzyme, polypeptide, peptide or other amino acid sequence, and produce a nucleic acid fragment of a codon-optimized coding region which encodes the amino acid product.
Ta ble 3
Sequence Codon (frequency: per thousand)
u uu 12.4 UCU 17.9 UAU 8.3 UGU 13.8 u uc 22 UCC 13.8 UAC 31.7 UGC 11
U UA 9.6 UCA 45.5 UAA 0 UGA 0
U UG 11 UCG 6.9 UAG 0 UGG 20.7
CUU 11 ecu 17.9 CAU 2.8 CGU 9.6 cue 12.4 CCC 30.3 CAC 15.2 CGC 8.3
CUA 9.6 CCA 12.4 CAA 11 CGA 4.1
CUG 33.1 CCG 6.9 CAG 42.7 CGG 5.5
AUU 6.9 ACU 12.4 AAU 16.5 AGU 15.2
AUC 12.4 ACC 24.8 AAC 28.9 AGC 13.8
AUA 2.8 ACA 20.7 AAA 42.7 AGA 8.3
AUG 11 ACG 12.4 AAG 19.3 AGG 5.5
GU U 41.3 GCU 11 GAU 33.1 GGU 5.5 GUC 17.9 GCC 9.6 GAC 13.8 GGC 37.2
GUA 9.6 GCA 28.9 GAA 22 GGA 5.5
GUG 20.7 GCG 4.1 GAG 19.3 GGG 9.6
Table 4
Sequence Codon (frequency: per thousand)
ORF 40 U UU 24.8 UCU 11 UAU 8.3 UGU 13.8 u uc 9.6 UCC 39.9 UAC 31.7 UGC 11
U UA 8.3 UCA 5.5 UAA 0 UGA 0
U UG 11 UCG 4.1 UAG 0 UGG 20.7
CUU 11 ecu 17.9 CAU 12.4 CGU 9.6 cue 12.4 CCC 30.3 CAC 5.5 CGC 8.3
CUA 11 CCA 12.4 CAA 5.5 CGA 4.1
CUG 33.1 CCG 6.9 CAG 48.2 CGG 5.5
AUU 6.9 ACU 12.4 AAU 24.8 AGU 9.6
AUC 5.5 ACC 11 AAC 20.7 AGC 42.7
AUA 9.6 ACA 41.3 AAA 33.1 AGA 8.3
AUG 11 ACG 5.5 AAG 28.9 AGG 5.5
GU U 16.5 GCU 12.4 GAU 16.5 GGU 4.1
GUC 16.5 GCC 27.5 GAC 30.3 GGC 13.8
GUA 15.2 GCA 8.3 GAA 8.3 GGA 9.6
GUG 41.3 GCG 5.5 GAG 33.1 GGG 30.3
Table 5
Sequence Codon (frequency: per thousand)
ORF 39 U UU 12.4 UCU 17.9 UAU 22 UGU 5.5 u uc 22 UCC 13.8 UAC 17.9 UGC 19.3
U UA 4.1 UCA 45.5 UAA 0 UGA 0
U UG 11 UCG 5.5 UAG 0 UGG 20.7
CUU 9.6 ecu 12.4 CAU 12.4 CGU 2.8 cue 24.8 CCC 44.1 CAC 5.5 CGC 5.5
CUA 5.5 CCA 6.9 CAA 5.5 CGA 6.9
CUG 31.7 CCG 4.1 CAG 48.2 CGG 8.3
AUU 8.3 ACU 9.6 AAU 16.5 AGU 15.2 AUC 8.3 ACC 22 AAC 28.9 AGC 15.2
AUA 5.5 ACA 17.9 AAA 42.7 AGA 11
AUG 11 ACG 20.7 AAG 19.3 AGG 6.9
GU U 24.8 GCU 28.9 GAU 26.2 GGU 9.6
GUC 22 GCC 13.8 GAC 20.7 GGC 13.8
GUA 11 GCA 8.3 GAA 8.3 GGA 20.7
GUG 31.7 GCG 2.8 GAG 33.1 GGG 13.8
Table 6
Sequence Codon (frequency: per thousand)
ORF 35 UUU 19.3 UCU 12.4 UAU 22 UGU 13.8 uuc 15.2 UCC 23.4 UAC 17.9 UGC 11
U UA 5.5 UCA 17.9 UAA 0 UGA 0
U UG 13.8 UCG 20.7 UAG 0 UGG 20.7
CUU 6.9 ecu 12.4 CAU 9.6 CGU 1.4 cue 13.8 CCC 44.1 CAC 8.3 CGC 4.1
CUA 5.5 CCA 6.9 CAA 27.5 CGA 2.8
CUG 41.3 CCG 4.1 CAG 26.2 CGG 13.8
AUU 13.8 ACU 11 AAU 9.6 AGU 11
AUC 5.5 ACC 46.8 AAC 35.8 AGC 27.5
AUA 2.8 ACA 6.9 AAA 20.7 AGA 5.5
AUG 11 ACG 5.5 AAG 41.3 AGG 13.8
GU U 41.3 GCU 19.3 GAU 11 GGU 8.3
GUC 17.9 GCC 19.3 GAC 35.8 GGC 26.2
GUA 9.6 GCA 11 GAA 28.9 GGA 9.6
GUG 20.7 GCG 4.1 GAG 12.4 GGG 13.8
Table 7
Sequence Codon (frequency: per thousand)
ORF 30 U UU 24.8 UCU 16.5 UAU 22 UGU 13.8 u uc 9.6 UCC 26.2 UAC 17.9 UGC 11
U UA 5.5 UCA 17.9 UAA 0 UGA 0
U UG 6.9 UCG 11 UAG 0 UGG 20.7
CUU 31.7 ecu 37.2 CAU 5.5 CGU 2.8 cue 16.5 CCC 15.2 CAC 12.4 CGC 2.8
CUA 6.9 CCA 12.4 CAA 9.6 CGA 8.3
CUG 19.3 CCG 2.8 CAG 44.1 CGG 5.5
AUU 5.5 ACU 12.4 AAU 16.5 AGU 13.8
AUC 12.4 ACC 11 AAC 28.9 AGC 27.5
AUA 4.1 ACA 41.3 AAA 20.7 AGA 16.5
AUG 11 ACG 5.5 AAG 41.3 AGG 5.5
GUU 15.2 GCU 27.5 GAU 33.1 GGU 4.1
GUC 28.9 GCC 15.2 GAC 13.8 GGC 13.8
GUA 6.9 GCA 8.3 GAA 22 GGA 9.6
GUG 38.6 GCG 2.8 GAG 19.3 GGG 30.3
Table 8
Sequence Codon (frequency: per thousand)
ORF28 uuu 12.4 UCU 27.5 UAU 22 UGU 13.8 uuc 22 UCC 20.7 UAC 17.9 UGC 11
UUA 5.5 UCA 13.8 UAA 0 UGA 0
UUG 6.9 UCG 4.1 UAG 0 UGG 20.7
CUU 31.7 ecu 37.2 CAU 9.6 CGU 2.8 cue 16.5 CCC 15.2 CAC 8.3 CGC 2.8
CUA 6.9 CCA 12.4 CAA 8.3 CGA 8.3
CUG 19.3 CCG 2.8 CAG 45.5 CGG 5.5
AUU 9.6 ACU 13.8 AAU 24.8 AGU 22
AUC 9.6 ACC 24.8 AAC 20.7 AGC 24.8
AUA 2.8 ACA 20.7 AAA 12.4 AGA 16.5
AUG 11 ACG 11 AAG 49.6 AGG 5.5
GUU 5.5 GCU 11 GAU 16.5 GGU 6.9
GUC 12.4 GCC 22 GAC 30.3 GGC 37.2
GUA 5.5 GCA 12.4 GAA 8.3 GGA 5.5
GUG 66.1 GCG 8.3 GAG 33.1 GGG 8.3
Table 9
Sequence Codon (frequency: per thousand)
ORF26 UUU 19.3 UCU 22 UAU 8.3 UGU 5.5 uuc 15.2 UCC 19.3 UAC 31.7 UGC 19.3
UUA 6.9 UCA 26.2 UAA 0 UGA 0 UUG 8.3 UCG 6.9 UAG 0 UGG 20.7
CUU 17.9 ecu 17.9 CAU 9.6 CGU 2.8 cue 17.9 CCC 30.3 CAC 8.3 CGC 12.4
CUA 8.3 CCA 12.4 CAA 5.5 CGA 4.1
CUG 27.5 CCG 6.9 CAG 48.2 CGG 8.3
AUU 5.5 ACU 11 AAU 24.8 AGU 17.9
AUC 12.4 ACC 46.8 AAC 20.7 AGC 20.7
AUA 4.1 ACA 6.9 AAA 12.4 AGA 5.5
AUG 11 ACG 5.5 AAG 49.6 AGG 8.3
GU U 5.5 GCU 19.3 GAU 11 GGU 22
GUC 11 GCC 19.3 GAC 35.8 GGC 16.5
GUA 5.5 GCA 11 GAA 22 GGA 12.4
GUG 67.5 GCG 4.1 GAG 19.3 GGG 6.9
Table 10
Sequence Codon (frequency: per thousand)
ORF 11 u uu 23.4 UCU 16.5 UAU 27.5 UGU 17.9 u uc 11 UCC 30.3 UAC 12.4 UGC 6.9
U UA 2.8 UCA 11 UAA 0 UGA 0
U UG 16.5 UCG 5.5 UAG 0 UGG 20.7
CUU 4.1 ecu 15.2 CAU 12.4 CGU 1.4 cue 8.3 CCC 22 CAC 5.5 CGC 6.9
CUA 4.1 CCA 19.3 CAA 17.9 CGA 4.1
CUG 51 CCG 11 CAG 35.8 CGG 11
AUU 9.6 ACU 12.4 AAU 16.5 AGU 15.2
AUC 9.6 ACC 24.8 AAC 28.9 AGC 34.4
AUA 2.8 ACA 20.7 AAA 12.4 AGA 6.9
AUG 11 ACG 12.4 AAG 49.6 AGG 11
GU U 15.2 GCU 28.9 GAU 16.5 GGU 5.5
GUC 16.5 GCC 13.8 GAC 30.3 GGC 37.2
GUA 16.5 GCA 8.3 GAA 22 GGA 5.5
GUG 41.3 GCG 2.8 GAG 19.3 GGG 9.6
Table 11
Sequence Codon (frequency: per thousand) ORF 2 U UU 22 UCU 37.2 UAU 13.8 UGU 8.3
U UC 12.4 UCC 15.2 UAC 26.2 UGC 16.5
U UA 5.5 UCA 11 UAA 0 UGA 0
U UG 5.5 UCG 2.8 UAG 0 UGG 20.7
CUU 31.7 ecu 11 CAU 12.4 CGU 2.8 cue 16.5 CCC 19.3 CAC 5.5 CGC 17.9
CUA 6.9 CCA 16.5 CAA 9.6 CGA 2.8
CUG 20.7 CCG 20.7 CAG 44.1 CGG 6.9
AUU 6.9 ACU 12.4 AAU 33.1 AGU 30.3
AUC 11 ACC 26.2 AAC 12.4 AGC 16.5
AUA 4.1 ACA 20.7 AAA 20.7 AGA 4.1
AUG 11 ACG 11 AAG 41.3 AGG 6.9
GU U 15.2 GCU 28.9 GAU 16.5 GGU 13.8
GUC 28.9 GCC 13.8 GAC 30.3 GGC 19.3
GUA 6.9 GCA 8.3 GAA 28.9 GGA 13.8
GUG 38.6 GCG 2.8 GAG 12.4 GGG 11
Table 12
Sequence Codon (frequency: per thousand)
ORF 1 UUU 6.9 UCU 12.4 UAU 8.3 UGU 5.5
UUC 27.5 UCC 24.8 UAC 31.7 UGC 19.3
U UA 2.8 UCA 16.5 UAA 0 UGA 0
U UG 16.5 UCG 22 UAG 0 UGG 20.7
CUU 2.8 ecu 11 CAU 2.8 CGU 1.4 cue 8.3 CCC 20.7 CAC 15.2 CGC 4.1
CUA 4.1 CCA 16.5 CAA 5.5 CGA 2.8
CUG 52.3 CCG 19.3 CAG 48.2 CGG 15.2
AUU 5.5 ACU 9.6 AAU 9.6 AGU 11
AUC 12.4 ACC 22 AAC 35.8 AGC 26.2
AUA 4.1 ACA 17.9 AAA 12.4 AGA 4.1
AUG 11 ACG 20.7 AAG 49.6 AGG 13.8
GU U 5.5 GCU 8.3 GAU 11 GGU 4.1
GUC 12.4 GCC 19.3 GAC 35.8 GGC 13.8
GUA 5.5 GCA 11 GAA 8.3 GGA 9.6
GUG 66.1 GCG 15.2 GAG 33.1 GGG 30.3 Table 13
Sequence Codon (frequency: per thousand)
IAU UUU 13.8 UCU 0 UAU 13.8 UGU
uuc 20.7 UCC 51 UAC 26.2 UGC
UUA 0 UCA 0 UAA 0 UGA
U UG 0 UCG 0 UAG 0 UGG
CUU 0 ecu 16.5 CAU 4.1 CGU 0 cue 0 CCC 26.2 CAC 13.8 CGC 0
CUA 0 CCA 24.8 CAA 11 CGA 12.4
CUG 86.8 CCG 0 CAG 42.7 CGG 12.4
AUU 6.9 ACU 0 AAU 15.2 AGU 0
AUC 15.2 ACC 45.5 AAC 30.3 AGC 62
AUA 0 ACA 24.8 AAA 23.4 AGA
AUG 11 ACG 0 AAG 38.6 AGG
GU U 0 GCU 0 GAU 12.4 GGU 0
GUC 46.8 GCC 27.5 GAC 34.4 GGC 19.3
GUA 0 GCA 26.2 GAA 15.2 GGA
GUG 42.7 GCG 0 GAG 26.2 GGG
Table 14
Sequence Codon (frequency: per thousand)
1AM UUU 0 UCU 0 UAU 0 UGU 11 u uc 34.4 UCC 41.3 UAC 39.9 UGC
U UA 0 UCA 0 UAA 0 UGA
U UG 0 UCG 0 UAG 0 UGG
CUU 0 ecu 17.9 CAU 4.1 CGU 0 cue 0 CCC 20.7 CAC 13.8 CGC 0
CUA 0 CCA 28.9 CAA 4.1 CGA 1.4
CUG 86.8 CCG 0 CAG 49.6 CGG
AUU 5.5 ACU 0 AAU 9.6 AGU
AUC 16.5 ACC 44.1 AAC 35.8 AGC
AUA 0 ACA 26.2 AAA 19.3 AGA 0
AUG 11 ACG 0 AAG 42.7 AGG 0 GUU 0 GCU 0 GAU 33.1 GGU 0
GUC 19.3 GCC 52.3 GAC 13.8 GGC 23.4
GUA 0 GCA 1.4 GAA 12.4 GGA 34.4
GUG 70.2 GCG 0 GAG 28.9 GGG 0
Table 15
Sequence Codon (frequency: per thousand)
BASE UUU 11 UCU 19.3 UAU 9.7 UGU 5.5 uuc 24.8 UCC 31.7 UAC 29 UGC 19.3
UUA 2.8 UCA 11 UAA 0 UGA 0
UUG 6.9 UCG 8.3 UAG 0 UGG 22.1
CUU 5.5 ecu 13.8 CAU 5.5 CGU 5.5 cue 16.6 CCC 26.2 CAC 13.8 CGC 1.4
CUA 5.5 CCA 17.9 CAA 8.3 CGA 8.3
CUG 45.5 CCG 9.7 CAG 44.1 CGG 5.5
AUU 5.5 ACU 9.7 AAU 13.8 AGU 6.9
AUC 17.9 ACC 33.1 AAC 30.3 AGC 34.5
AUA 0 ACA 19.3 AAA 20.7 AGA 13.8
AUG 9.7 ACG 9.7 AAG 41.4 AGG 5.5
GUU 4.1 GCU 5.5 GAU 11 GGU 4.1
GUC 34.5 GCC 24.8 GAC 35.9 GGC 20.7
GUA 4.1 GCA 16.6 GAA 16.6 GGA 17.9
GUG 48.3 GCG 6.9 GAG 24.8 GGG 17.9
Table 16
Sequence Codon (frequency: per thousand)
201 UUU 11.8 UCU 23.5 UAU 17.6 UGU 11.8 uuc 17.6 UCC 27.5 UAC 33.3 UGC 15.7
UUA 0 UCA 17.6 UAA 0 UGA 0
UUG 0 UCG 0 UAG 0 UGG 17.6
CUU 0 ecu 21.6 CAU 5.9 CGU 0 cue 0 CCC 17.6 CAC 7.8 CGC 5.9
CUA 0 CCA 27.5 CAA 2 CGA 7.8
CUG 78.4 CCG 0 CAG 47.1 CGG 9.8 AUU 9.8 ACU 21.6 AAU 13.7 AGU 17.6
AUC 21.6 ACC 31.4 AAC 17.6 AGC 29.4
AUA 0 ACA 25.5 AAA 19.6 AGA 7.8
AUG 9.8 ACG 0 AAG 31.4 AGG 7.8
GU U 0 GCU 9.8 GAU 23.5 GGU 0
GUC 27.5 GCC 15.7 GAC 23.5 GGC 33.3
GUA 0 GCA 9.8 GAA 19.6 GGA 45.1
GUG 54.9 GCG 0 GAG 25.5 GGG 21.6
Table 17
Sequence Codon (frequency: per thousand)
10A UUU 9.8 UCU 29.3 UAU 21.5 UGU 13.7
u uc 11.7 UCC 21.5 UAC 23.4 UGC 11.7
U UA 0 UCA 15.6 UAA 0 UGA 0
U UG 0 UCG 0 UAG 0 UGG 23.4
CUU 0 ecu 21.5 CAU 7.8 CGU 0 cue 0 CCC 19.5 CAC 7.8 CGC 2
CUA 0 CCA 27.3 CAA 0 CGA 7.8
CUG 78.1 CCG 0 CAG 50.8 CGG 5.9
AUU 11.7 ACU 19.5 AAU 11.7 AGU 23.4
AUC 17.6 ACC 31.2 AAC 17.6 AGC 39.1
AUA 0 ACA 25.4 AAA 27.3 AGA 7.8
AUG 13.7 ACG 0 AAG 33.2 AGG 3.9
GU U 0 GCU 11.7 GAU 19.5 GGU 0
GUC 31.2 GCC 15.6 GAC 21.5 GGC 33.2
GUA 0 GCA 19.5 GAA 19.5 GGA 43
GUG 48.8 GCG 0 GAG 23.4 GGG 19.5
For example, the codon frequency of Table 5 or Table 6, or a codon frequency within 10% thereof, is particularly well suited to enhance expression of a selected gene product in muscle, and more particularly, skeletal muscle. In another example, the codon frequency of Table 9, Table 10, or Table 11, or a codon frequency within 10% thereof, is particularly well suited to enhance expression of a selected gene product in liver. In still another example, the codon frequency of Table 16 is particularly well suited to enhance expression of a selected gene product in respiratory epithelium (e.g., lung). In one embodiment, expression is mediated by an AAV. However, the codon frequency of these tables are useful in other methods and for other delivery vectors.
The methods provided herein are designed as the primary consideration to select the frequently used codon for a given amino acid as the primary consideration. However, as a secondary or tertiary consideration, the methods described herein may further select a codon or modify a selected sequence to exclude undesirable structural elements, e.g., (a) restriction sites, CpG islands, (b) exclusion of a hairpin turn in the initial polynucleotide sequence; (c) exclusion of a repeat element in the initial polynucleotide sequence; (d) exclusion of a ribosome binding site in the initial polynucleotide sequence; (e) exclusion of a
polyadenylation signal in the initial polynucleotide sequence; (f) exclusion of a splice site in the initial polynucleotide sequence; (g) exclusion of an open reading frame in each possible 5' reading frame in the initial polynucleotide sequence; (h) exclusion of a polynucleotide sequence that facilitates RNA degradation in the initial polynucleotide sequence; (i) exclusion of an RNA polymerase termination signal in the initial polynucleotide sequence; (J) exclusion of a transcriptional promoter in the initial polynucleotide sequence; (k) exclusion of an immunostimulatory sequence in the initial polynucleotide sequence; (1) incorporation of an immunostimulatory sequence in the initial polynucleotide sequence; (mi) exclusion of an RNA methylation signal in the initial polynucleotide sequence; (n) exclusion of a selenocysteine incorporation signal in the initial polynucleotide sequence; (o) exclusion of an RNA editing sequence in the initial polynucleotide sequence; (p) exclusion of an RNAi-targeted sequence in the initial polynucleotide sequence; and/or (q) exclusion of an inverted repeat within the first 45 nucleotides encoding said synthetic polypeptide in the initial polynucleotide sequence. See, e.g., US Patent Publication No. 20130196864, which is incorporated by reference herein.
Methods of modifying an existing nucleic acid sequence to provide a synonymous codon for a selected amino acid and/or back-translating a selected amino acid sequence into a desired nucleic acid have been described. For example, web-based or commercially available computer programs, as well as service based companies may be used to back translate the amino acids sequences to nucleic acid coding sequences, including both RNA and/or cDNA. See, e.g., backtranseq by EMBOSS, http://www.ebi.ac.uk/Tools/st/ ; Gene Infinity (http://www.geneinfinity.org/sms-/sms_backtranslation.html); ExPasy
(http://www.expasy.org/tools/). A number of options are available for performing the changes to the codons or for synthesizing the codon-optimized coding regions designed as described herein. Such modifications or synthesis can be performed using standard and routine molecular biological manipulations well known to those of ordinary skill in the art. In one approach, a series of complementary oligonucleotide pairs of 80-90 nucleotides each in length and spanning the length of the desired sequence are synthesized by standard methods. These oligonucleotide pairs are synthesized such that upon annealing, they form double stranded fragments of 80-90 base pairs, containing cohesive ends, e.g., each oligonucleotide in the pair is synthesized to extend 3, 4, 5, 6, 7, 8, 9, 10, or more bases beyond the region that is complementary to the other oligonucleotide in the pair. The single- stranded ends of each pair of oligonucleotides is designed to anneal with the single-stranded end of another pair of oligonucleotides. The oligonucleotide pairs are allowed to anneal, and approximately five to six of these double-stranded fragments are then allowed to anneal together via the cohesive single stranded ends, and then they ligated together and cloned into a standard bacterial cloning vector, for example, a TOPO® vector available from Invitrogen Corporation, Carlsbad, Calif. The construct is then sequenced by standard methods. Several of these constructs consisting of 5 to 6 fragments of 80 to 90 base pair fragments ligated together, i.e., fragments of about 500 base pairs, are prepared, such that the entire desired sequence is represented in a series of plasmid constructs. The inserts of these plasmids are then cut with appropriate restriction enzymes and ligated together to form the final construct. The final construct is then cloned into a standard bacterial cloning vector, and sequenced. Additional methods would be immediately apparent to the skilled artisan. In addition, gene synthesis is readily available commercially.
As described above, the term "about" when used to modify a numerical value means a variation of ±10%, unless otherwise specified.
The terms "identical" or percent "identity," in the context of two or more nucleic acids or polypeptide sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same (i.e., about 70% identity, preferably 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or higher identity) over a specified region (e.g., any one of the modified ORFs provided herein when compared and aligned for maximum correspondence over a comparison window or designated region) as measured using a BLAST or BLAST 2.0 sequence comparison algorithms with default parameters described below, or by manual alignment and visual inspection (see, e.g., NCBI web site or the like). As another example, polynucleotide sequences can be compared using Fasta, a program in GCG Version 6.1. Fasta provides alignments and percent sequence identity of the regions of the best overlap between the query and search sequences. For instance, percent sequence identity between nucleic acid sequences can be determined using Fasta with its default parameters (a word size of 6 and the NOP AM factor for the scoring matrix) as provided in GCG Version 6.1, herein incorporated by reference. Generally, these programs are used at default settings, although one skilled in the art can alter these settings as needed. Alternatively, one of skill in the art can utilize another algorithm or computer program that provides at least the level of identity or alignment as that provided by the referenced algorithms and programs. This definition also refers to, or can be applied to, the compliment of a sequence. The definition also includes sequences that have deletions and/or additions, as well as those that have substitutions. As described below, the preferred algorithms can account for gaps and the like. Preferably, identity exists over a region that is at least about 25, 50, 75, 100, 150, 200 amino acids or nucleotides in length, and oftentimes over a region that is 225, 250, 300, 350, 400, 450, 500 amino acids or nucleotides in length or over the full-length of an amino acid or nucleic acid sequences.
Typically, when an alignment is prepared based upon an amino acid sequence, the alignment contains insertions and deletions which are so identified with respect to a reference AAV sequence and the numbering of the amino acid residues is based upon a reference scale provided for the alignment. However, any given AAV sequence may have fewer amino acid residues than the reference scale. In the present invention, when discussing the parental sequence, the term "the same position" or the "corresponding position" refers to the amino acid located at the same residue number in each of the sequences, with respect to the reference scale for the aligned sequences. However, when taken out of the alignment, each of the proteins may have these amino acids located at different residue numbers. Alignments are performed using any of a variety of publicly or commercially available Multiple Sequence Alignment Programs. Sequence alignment programs are available for amino acid sequences, e.g., the "Clustal X", "MAP", "PIMA", "MSA", "BLOCKMAKER", "MEME", and "Match-Box" programs. Generally, any of these programs are used at default settings, although one of skill in the art can alter these settings as needed. Alternatively, one of skill in the art can utilize another algorithm or computer program which provides at least the level of identity or alignment as that provided by the referenced algorithms and programs. See, e.g., J. D. Thomson et al, Nucl. Acids. Res., "A comprehensive comparison of multiple sequence alignments", 27(13):2682-2690 (1999).
As used throughout this specification and the claims, the terms "comprise" and "contain" and its variants including, "comprises", "comprising", "contains" and
"containing", among other variants, is inclusive of other components, elements, integers, steps and the like. The term "consists of or "consisting of are exclusive of other components, elements, integers, steps and the like.
GENE PRODUCTS
As described herein, a synonymously modified gene designed as described herein is typically engineered into an expression cassette. An expression cassette as described herein contains the modified gene which has codons preferentially modified and selected to express a product in a target tissue, which is operably linked to expression control sequences which direct expression thereof. Such an expression cassette may also include expression control sequences useful for transcription initiation, termination, promoter and enhancer sequences; efficient RNA processing signals such as splicing and polyadenylation (polyA) signals; sequences that stabilize cytoplasmic mRNA; sequences that enhance translation efficiency (i.e., Kozak consensus sequence); sequences that enhance protein stability; and when desired, sequences that enhance secretion of the encoded product. Alternatively, or additionally, such regulatory expression elements may be located outside of the expression cassette, e.g., within another region of a vector into which the expression cassette is engineered.
Provided in Fig. 5 and the sequence listing (SEQ ID Nos: 13-29), herein are the plasmid constructs utilized the Example below. The plasmids contain sequences encoding an anti-HIV antibody (3bcnl 17 antibody. See, Scheid et al, Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science. 2011 Sep 16;333(6049): 1633-7. Epub 2011 Jul 14, which is incorporated herein by reference). Specific fragments of the sequences are identified and are, in one embodiment, of particular interest. These fragments may be used in conjunction with other fragments described herein, or other complementary fragments as known in the art. For example, certain fragments of interest include the constant regions of the heavy and light chains of an antibody such as the anti-SIV or anti-HIV antibody of the examples. These sequences, having been optimized for expression in a particular tissue type (e.g., liver, respiratory epithelial cells (e.g., lung)) may be utilized in conjunction with the variable regions of other antibodies, as described further below. The variable regions may be optimized for expression in the desired tissue using the codon frequency tables described herein. See Tables 3 - 12, 16, 17. Optionally, Tables 2, 23, 24, 15 may be used in conjunction with the methods and constructs described herein.
Desirable fragments of the plasmids include 5 ' and 3' IT sequences, promoters, enhancers, TATA box, introns, IRES, F2A linkers, furin sites, forward primers, reverse primers, polyA signals. Other desirable fragments include the following:
Figure imgf000025_0001
Corresponding regions of the ORFs described herein or other desirable sequences can be readily determined using standard alignment techniques known in the art and described herein.
Therapeutic Transgenes
A nucleotide sequence encoding any of a number of different therapeutic transgenes may be selected for codon modification to enhance tissue-preferential expression as described herein. Useful therapeutic products encoded by the transgene include hormones and growth and differentiation factors including, without limitation, insulin, glucagon, growth hormone (GH), parathyroid hormone (PTH), growth hormone releasing factor (GRF), follicle stimulating hormone (FSH), luteinizing hormone (LH), human chorionic gonadotropin (hCG), vascular endothelial growth factor (VEGF), angiopoietins, angiostatin, granulocyte colony stimulating factor (GCSF), erythropoietin (EPO), connective tissue growth factor (CTGF), basic fibroblast growth factor (bFGF), acidic fibroblast growth factor (aFGF), epidermal growth factor (EGF), platelet-derived growth factor (PDGF), insulin growth factors I and II (IGF-I and IGF-II), any one of the transforming growth factor a superfamily, including TGFa, activins, inhibins, or any of the bone morphogenic proteins (BMP) BMPs 1-15 as well as TGFb proteins, any one of the heregluin/neuregulin/ARIA/neu differentiation factor (NDF) family of growth factors, nerve growth factor (NGF), brain- derived neurotrophic factor (BDNF), neurotrophins NT-3 and NT -4/5, ciliary neurotrophic factor (CNTF), glial cell line derived neurotrophic factor (GDNF), neurturin, agrin, any one of the family of semaphorins/collapsins, netrin-1 and netrin-2, hepatocyte growth factor (HGF), ephrins, noggin, sonic hedgehog and tyrosine hydroxylase.
Other useful transgene products include proteins that regulate the immune system including, without limitation, cytokines and lymphokines such as thrombopoietin (TPO), interleukins (IL) IL-1 through IL-25 (including IL-2, IL-4, IL-12 and IL-18), monocyte chemoattractant protein, leukemia inhibitory factor, granulocyte-macrophage colony stimulating factor, Fas ligand, tumor necrosis factors a and β, interferons α, β, TGFb and γ, stem cell factor, flk-2/flt3 ligand. Gene products produced by the immune system are also useful in the invention. These include, without limitations, immunoglobulins IgG, IgM, IgA, IgD and IgE, chimeric immunoglobulins, humanized antibodies, single chain antibodies, T cell receptors, chimeric T cell receptors, single chain T cell receptors, class I and class II
MHC molecules, as well as engineered immunoglobulins and MHC molecules. Useful gene products also include complement regulatory proteins such as complement regulatory proteins, membrane cofactor protein (MCP), decay accelerating factor (DAF), CRl, CF2 and CD59.
Still other useful gene products include any one of the receptors for the hormones, growth factors, cytokines, lymphokines, regulatory proteins and immune system proteins. The invention encompasses receptors for cholesterol regulation and/or lipid modulation, including the low density lipoprotein (LDL) receptor, high density lipoprotein (HDL) receptor, the very low density lipoprotein (VLDL) receptor, and scavenger receptors. The invention also encompasses gene products such as members of the steroid hormone receptor superfamily including glucocorticoid receptors and estrogen receptors, Vitamin D receptors and other nuclear receptors. In addition, useful gene products include transcription factors such as jun, fos, max, mad, serum response factor (SRF), AP-1, AP2, myb, MyoD and myogenin, ETS-box containing proteins, TFE3, E2F, ATF1, ATF2, ATF3, ATF4, ZF5, NFAT, CREB, HNF-4, C/EBP, SP1, CCAAT-box binding proteins, interferon regulation factor (IRF-1), Wilms tumor protein, ETS-binding protein, STAT, GATA-box binding proteins, e.g., GATA-3, and the forkhead family of winged helix proteins. Other useful gene products include, carbamoyl synthetase I, ornithine
transcarbamylase, arginosuccinate synthetase, arginosuccinate lyase, arginase,
fumarylacetacetate hydrolase, phenylalanine hydroxylase, alpha- 1 antitrypsin, glucose-6- phosphatase, porphobilinogen deaminase, cystathione beta-synthase, branched chain ketoacid decarboxylase, albumin, isovaleryl-coA dehydrogenase, propionyl CoA carboxylase, methyl malonyl CoA mutase, glutaryl CoA dehydrogenase, insulin, beta- glucosidase, pyruvate carboxylate, hepatic phosphorylase, phosphorylase kinase, glycine decarboxylase, H-protein, T-protein, a cystic fibrosis transmembrane regulator (CFT ) sequence, and a dystrophin cDNA sequence. Still other useful gene products include enzymes such as may be useful in enzyme replacement therapy, which is useful in a variety of conditions resulting from deficient activity of enzyme. For example, enzymes that contain mannose-6-phosphate may be utilized in therapies for lysosomal storage diseases (e.g., a suitable gene includes that encoding β -glucuronidase (GUSB)).
Still other useful gene products include those used for treatment of hemophilia, including hemophilia B (including Factor IX) and hemophilia A (including Factor VIII and its variants, such as the light chain and heavy chain of the heterodimer and the B-deleted domain; US Patent 6,200,560 and US Patent 6,221 ,349). The present invention is not limited to any specific Factor VIII sequence. Many natural and recombinant forms of Factor VIII have been isolated and generated. Examples of naturally occurring and recombinant forms of Factor VII can be found in the patent and scientific literature including, US Patent No.
5,563,045, US Patent No. 5,451,521, US Patent No. 5,422,260, US Patent No. 5,004,803, US Patent No. 4,757,006, US Patent No. 5,661,008, US Patent No. 5,789,203, US Patent No. 5,681,746, US Patent No. 5,595,886, US Patent No. 5,045,455, US Patent No. 5,668,108, US Patent No. 5,633,150, US Patent No. 5,693,499, US Patent No. 5,587,310, US Patent No. 5,171,844, US Patent No. 5,149,637, US Patent No. 5,1 12,950, US Patent No. 4,886,876, WO 94/11503, WO 87/07144, WO 92/16557, WO 91/09122, WO 97/03195, WO 96/21035, WO 91/07490, EP 0 672 138, EP 0 270 618, EP 0 182 448, EP 0 162 067, EP 0 786 474, EP 0 533 862, EP 0 506 757, EP 0 874 057,EP 0 795 021 , EP 0 670 332, EP 0 500 734, EP 0 232 1 12, EP 0 160 457, Sanberg et al., XXth Int. Congress of the World Fed. Of Hemophilia (1992), and Lind et al., Eur. J. Biochem., 232: 19 (1995).
Also included herein are non-naturally occurring gene sequences include antisense molecules and catalytic nucleic acids, such as ribozymes, which could be used to reduce overexpression of a target. "Knockdown gene therapy" is directed towards a gene product which is associated with a disease or conditions in which the targeted gene is overexpressed, but which is not entirely extinguished by the therapy. Molecules such as microR A and small interfering RNA (siR A) may be delivered to accomplish knock out or knock down.
Reduction and/or modulation of expression of a gene is particularly desirable for treatment of hyperproliferative conditions characterized by hyperproliferating cells, as are cancers and psoriasis. Target polypeptides include those polypeptides which are produced exclusively or at higher levels in hyperproliferative cells as compared to normal cells.
Target antigens include polypeptides encoded by oncogenes such as myb, myc, fyn, and the translocation gene bcr/abl, ras, src, P53, neu, trk and EGRF. In addition to oncogene products as target antigens, target polypeptides for anti-cancer treatments and protective regimens include variable regions of antibodies made by B cell lymphomas and variable regions of T cell receptors of T cell lymphomas which, in some embodiments, are also used as target antigens for autoimmune disease. Other tumor associated polypeptides can be used as target polypeptides such as polypeptides which are found at higher levels in tumor cells including the polypeptide recognized by monoclonal antibody 17 1 A and folate binding polypeptides.
Other suitable therapeutic polypeptides and proteins include those which may be useful for treating individuals suffering from autoimmune diseases and disorders by conferring a broad based protective immune response against targets that are associated with autoimmunity including cell receptors and cells which produce "self-directed antibodies. T cell mediated autoimmune diseases include Rheumatoid arthritis (RA), multiple sclerosis (MS), Sjogren's syndrome, sarcoidosis, insulin dependent diabetes mellitus (IDDM), autoimmune thyroiditis, reactive arthritis, ankylosing spondylitis, scleroderma, polymyositis, dermatomyositis, psoriasis, vasculitis, Wegener's granulomatosis, Crohn's disease and ulcerative colitis. Each of these diseases is characterized by T cell receptors (TCRs) and antibodies (Ab) that bind to endogenous antigens and initiate the inflammatory cascade associated with autoimmune diseases.
Other suitable therapeutic polypeptides and protein include those useful for treating individuals suffering from a rare disease. Such rare disease include, e.g.,
acrocephalosyndactylia, Acrodermatitis, Addison Disease, Adie Syndrome, Alagille
Syndrome, Amylose, Amyotrophic Lateral Sclerosis, Angelman Syndrome, Angiolymphoid Hyperplasia with Eosinophilia, Arnold-Chiari Malformation, juvenile rheumatoid arthritis, Asperger Syndrome, Bardet-Biedl Syndrome, Barrett Esophagus, Beckwith- Wiedemann Syndrome, Behcet Syndrome, Bloom Syndrome, Bowen's Disease, Brachial Plexus Neuropathies, Brown-Sequard Syndrome, Budd-Chiari Syndrome, Burkitt Lymphoma, Carcinoma 256, Walker Caroli Disease, Charcot-Marie-Tooth Disease, Chediak-Higashi Syndrome, Chiari-Frommel Syndrome, Chondrodysplasia Punctata, Colonic Pseudo- Obstruction, Colorectal Neoplasms, Hereditary Nonpolyposis, Craniofacial Dysostosis, Creutzfeldt- Jakob Syndrome, Crohn Disease, Cushing Syndrome, Cystic Fibrosis, Dandy- Walker Syndrome, De Lange Syndrome, Dementia, Vascular Dermatitis, Herpetiformis, DiGeorge Syndrome, Diffuse Cerebral Sclerosis of Schilder, Duane Retraction Syndrome, Dupuytren Contracture, Ebstein Anomaly, Eisenmenger Complex, Ellis-Van Creveld Syndrome, Encephalitis, Enchondromatosis, Epidermal Necrolysis, Toxic Facial
Hemiatrophy, Factor XII Deficiency, Fanconi Anemia, Felty's Syndrome, Fibrous
Dysplasia, Polyostotic, Fox-Fordyce Disease, Friedreich Ataxia, Fusobacterium, Gardner Syndrome, Gaucher Disease, Gerstmann Syndrome, Giant Lymph Node Hyperplasia, Glycogen Storage Disease Type I, Glycogen Storage Disease Type II, Glycogen Storage Disease Type IV, Glycogen Storage Disease Type V, Glycogen Storage Disease Type VII, Goldenhar Syndrome, Guillain-Barre Syndrome, Hallermann's Syndrome, Hamartoma Syndrome, Multiple Hartnup Disease, Hepatolenticular Degeneration, Hepatolenticular Degeneration, Hereditary Sensory and Motor Neuropathy Hirschsprung Disease, Histiocytic Necrotizing Lymphadenitis, Histiocytosis, Langerhans-Cell Hodgkin Disease, Horner Syndrome, Huntington Disease, Hyperaldosteronism, Hyperostosis, Diffuse Idiopathic Skeletal, Hypopituitarism, Inappropriate ADH Syndrome, Intestinal Polyps
Isaacs Syndrome, Kartagener Syndrome, Kearns-Sayre Syndrome, Klippel-Feil Syndrome, Klippel-Trenaunay- Weber Syndrome, Kluver-Bucy Syndrome, Korsakoff Syndrome, Lafora Disease, Lambert-Eaton Myasthenic Syndrome, Landau-Kleffher Syndrome, Langer- Giedion Syndrome, Leigh Disease, Lesch-Nyhan Syndrome, Leukodystrophy, Globoid Cell, Li-Fraumeni Syndrome, Long QT Syndrome, Machado-Joseph Disease, Mallory- Weiss Syndrome, Marek Disease, Marfan Syndrome, Meckel Diverticulum, Meige Syndrome, Melkersson-Rosenthal Syndrome, Meniere Disease, Mikulicz' Disease, Miller Fisher Syndrome, Mobius Syndrome, Moyamoya Disease, Mucocutaneous Lymph Node
Syndrome, Mucopolysaccharidosis I, Mucopolysaccharidosis II, Mucopolysaccharidosis III, Mucopolysaccharidosis IV, Mucopolysaccharidosis VI, Multiple Endocrine Neoplasia Type 1, Munchausen Syndrome by Proxy, Muscular Atrophy, Spinal Neuroaxonal Dystrophies, Neuromyelitis Optica, Neuronal Ceroid-Lipofuscinoses, Niemann-Pick Diseases, Noonan Syndrome, Optic Atrophies, Hereditary Osteitis Deformans, Osteochondritis,
Osteochondrodysplasias, Osteolysis, Essential, Paget Disease Extramammary, Paget' s Disease, Mammary, Panniculitis, Nodular Nonsuppurative, Papillon-Lefevre Disease, Paralysis, Pelizaeus-Merzbacher Disease, Pemphigus, Benign Familial Penile Induration, Pericarditis, Constrictive, Peroxisomal Disorders, Peutz-Jeghers Syndrome, Pick Disease of the Brain, Pierre Robin Syndrome, Pigmentation Disorders, Pityriasis Lichenoides, Polycystic Ovary Syndrome, Polyendocrinopathies, Autoimmune Prader-Willi Syndrome, Pupil Disorders, Rett Syndrome, Reye Syndrome, Rubinstein-Taybi Syndrome,
Sandhoff Disease, Sarcoma, Ewing's, Sjogren's Syndrome, Sjogren-Larsson Syndrome, Smith-Lemli-Opitz Syndrome, Spinal Muscular Atrophies of Childhood, Sturge- Weber Syndrome, Sweating, Gustatory, Takayasu Arteritis, Tangier Disease, Tay-Sachs Disease, Thromboangiitis Obliterans, Thyroiditis, Autoimmune, Tietze's Syndrome, Togaviridae Infections, Tolosa-Hunt Syndrome, Tourette Syndrome, Uveomeningoencephalitic Syndrome Waardenburg's Syndrome, Wegener Granulomatosis, Weil Disease, Werner Syndrome, Williams Syndrome, Wilms Tumor, Wolff-Parkinson- White Syndrome, Wolfram Syndrome, Wolman Disease, Zellweger Syndrome, Zollinger-Ellison Syndrome, and von Willebrand Diseases.
Immunogenic Transgenes
The nucleotide sequence encoding of any of a number of immunogenic transgenes may be selected for codon modification to enhance tissue-preferential expression as described herein. Examples of suitable immunogenic transgenes include those selected from a variety of viral families. Example of desirable viral families against which an immune response would be desirable include, the picornavirus family, which includes the genera rhinoviruses, which are responsible for about 50% of cases of the common cold; the genera enteroviruses, which include polioviruses, coxsackieviruses, echoviruses, and human enteroviruses such as hepatitis A virus; and the genera apthoviruses, which are responsible for foot and mouth diseases, primarily in non-human animals. Within the picornavirus family of viruses, target antigens include the VP1, VP2, VP3, VP4, and VPG. Other viral families include the astroviruses and the calcivirus family. The calcivirus family encompasses the Norwalk group of viruses, which are an important causative agent of epidemic gastroenteritis. Still another viral family desirable for use in targeting antigens for inducing immune responses in humans and non-human animals is the togavirus family, which includes the genera alphavirus, which include Sindbis viruses, oss iver virus, and Venezuelan, Eastern & Western Equine encephalitis, and rubivirus, including Rubella virus. The flaviviridae family includes dengue, yellow fever, Japanese encephalitis, St. Louis encephalitis and tick borne encephalitis viruses. Other target antigens may be generated from the Hepatitis C or the coronavirus family, which includes a number of non-human viruses such as infectious bronchitis virus (poultry), porcine transmissible gastroenteric virus (pig), porcine hemagglutinatin encephalomyelitis virus (pig), feline infectious peritonitis virus (cats), feline enteric coronavirus (cat), canine coronavirus (dog), and human respiratory coronaviruses, which may cause the common cold and/or non A, B or C hepatitis, and which include the putative cause of sudden acute respiratory syndrome (SARS). Within the coronavirus family, target antigens include the El (also called M or matrix protein), E2 (also called S or Spike protein), E3 (also called HE or hemagglutin elterose) glycoprotein (not present in all coronaviruses), or N (nucleocapsid). Still other antigens may be targeted against the arterivirus family and the rhabdovirus family. The rhabdovirus family includes the genera vesiculovirus (e.g., Vesicular Stomatitis Virus), and the general lyssavirus (e.g., rabies). Within the rhabdovirus family, suitable antigens may be derived from the G protein or the N protein. The family filoviridae, which includes hemorrhagic fever viruses such as Marburg and Ebola virus may be a suitable source of antigens. The paramyxovirus family includes parainfluenza Virus Type 1 , parainfluenza Virus Type 3, bovine parainfluenza Virus Type 3, rubulavirus (mumps virus, parainfluenza Virus Type 2, parainfluenza virus Type 4, Newcastle disease virus (chickens), rinderpest, morbillivirus, which includes measles and canine distemper, and pneumovirus, which includes respiratory syncytial virus. The influenza virus is classified within the family orthomyxovirus and is a suitable source of antigen (e.g., the HA protein, the Nl protein). The bunyavirus family includes the genera bunyavirus (California encephalitis, La Crosse), phlebovirus (Rift Valley Fever), hantavirus (puremala is a hemahagin fever virus), nairovirus (Nairobi sheep disease) and various unassigned bungaviruses. The arenavirus family provides a source of antigens against LCM and Lassa fever virus. Another source of antigens is the bornavirus family. The reovirus family includes the genera reovirus, rotavirus (which causes acute gastroenteritis in children), orbiviruses, and cultivirus (Colorado Tick fever, Lebombo (humans), equine encephalosis, blue tongue). The retrovirus family includes the sub family oncorivirinal which encompasses such human and veterinary diseases as feline leukemia virus, HTLVI and HTLVII, lentivirinal (which includes HIV, simian immunodeficiency virus, feline immunodeficiency virus, equine infectious anemia virus, and spumavirinal). The papovavirus family includes the sub-family polyomaviruses (BKU and JCU viruses) and the sub family papillomavirus (associated with cancers or malignant progression of papilloma). The adenovirus family includes viruses (EX, AD7, A D, O.B.) which cause respiratory disease and/or enteritis. The parvovirus family feline parvovirus (feline enteritis), feline panleucopeniavirus, canine parvovirus, and porcine parvovirus. The herpesvirus family includes the sub family alphaherpesvirinae, which encompasses the genera simplexvirus (HSVI, HSVII), varicellovirus (pseudorabies, varicella zoster) and the sub-family betaherpesvirinae, which includes the genera cytomegalovirus (HCMV, muromegalovirus) and the sub family gammaherpesvirinae, which includes the genera lymphocryptovirus, EBV (Burkitts lymphoma), human herpesviruses 6A, 6B and 7, Kaposi's sarcoma-associated herpesvirus and cercopithecine herpesvirus (B virus), infectious rhinotracheitis, Marek's disease virus, and rhadinovirus. The poxvirus family includes the sub family
chordopoxvirinae, which encompasses the genera orthopoxvirus (Variola major (Smallpox) and Vaccinia (Cowpox)), parapoxvirus, avipoxvirus, capripoxvirus, leporipoxvirus, suipoxvirus, and the sub family entomopoxvirinae. The hepadnavirus family includes the Hepatitis B virus. One unclassified virus which may be suitable source of antigens is the Hepatitis delta virus, Hepatitis E virus, and prions. Another virus which is a source of antigens is Nipan Virus. Still other viral sources may include avian infectious bursal disease virus and porcine respiratory and reproductive syndrome virus. The alphavirus family includes equine arteritis virus and various Encephalitis viruses.
The present invention may also encompass immunogens which are useful to immunize a human or non-human animal against other pathogens including bacteria, fungi, parasitic microorganisms or multicellular parasites which infect human and non-human vertebrates, or from a cancer cell or tumor cell. Examples of bacterial pathogens include pathogenic gram positive cocci include pneumococci; staphylococci (and the toxins produced thereby, e.g., enterotoxin B); and streptococci. Pathogenic gram negative cocci include meningococcus; gonococcus. Pathogenic enteric gram negative bacilli include enterobacteriaceae; pseudomonas, acinetobacteria and eikenella; melioidosis; salmonella; shigella; haemophilus; moraxella; H. ducreyi (which causes chancroid); brucella species (brucellosis); Francisella tularensis (which causes tularemia); Yersinia pestis (plague) and other yersinia (pasteurella); streptobacillus moniliformis and spirillum; Gram-positive bacilli include listeria monocytogenes; erysipelothrix rhusiopathiae; Corynebacterium diphtheria (diphtheria); cholera; B. anthracis (anthrax); donovanosis (granuloma inguinale); and bartonellosis. Diseases caused by pathogenic anaerobic bacteria include tetanus; botulism (Clostridum botulinum and its toxin); Clostridium perfringens and its epsilon toxin; other Clostridia; tuberculosis; leprosy; and other mycobacteria. Pathogenic spirochetal diseases include syphilis; treponematoses: yaws, pinta and endemic syphilis; and leptospirosis. Other infections caused by higher pathogen bacteria and pathogenic fungi include glanders (Burkholderia mallei); actinomycosis; nocardiosis; cryptococcosis, blastomycosis, histoplasmosis and coccidioidomycosis; candidiasis, aspergillosis, and mucormycosis; sporotrichosis; paracoccidiodomycosis, petriellidiosis, torulopsosis, mycetoma and chromomycosis; and dermatophytosis. Rickettsial infections include Typhus fever, Rocky Mountain spotted fever, Q fever (Coxiella burnetti), and Rickettsialpox. Examples of mycoplasma and chlamydial infections include: mycoplasma pneumoniae;
lymphogranuloma venereum; psittacosis; and perinatal chlamydial infections. Pathogenic eukaryotes encompass pathogenic protozoans and helminths and infections produced thereby include: amebiasis; malaria; leishmaniasis; trypanosomiasis; toxoplasmosis; Pneumocystis carinii; Trichans; Toxoplasma gondii; babesiosis; giardiasis; trichinosis; filariasis;
schistosomiasis; nematodes; trematodes or flukes; and cestode (tapeworm) infections.
Many of these organisms and/or the toxins produced thereby have been identified by the Centers for Disease Control [(CDC), Department of Health and Human Services, USA], as agents which have potential for use in biological attacks. For example, some of these biological agents, include, Bacillus anthracis (anthrax), Clostridium botulinum and its toxin (botulism), Yersinia pestis (plague), variola major (smallpox), Francisella tularensis (tularemia), and viral hemorrhagic fevers [filoviruses (e.g., Ebola, Marburg], and arenaviruses [e.g., Lassa, Machupo]), all of which are currently classified as Category A agents; Coxiella burnetti (Q fever); Brucella species (brucellosis), Burkholderia mallei
(glanders), Burkholderia pseudomallei (meloidosis), Ricinus communis and its toxin (ricin toxin), Clostridium perfringens and its toxin (epsilon toxin), Staphylococcus species and their toxins (enterotoxin B), Chlamydia psittaci (psittacosis), water safety threats (e.g., Vibrio cholerae, Crytosporidium parvum), Typhus fever (Richettsia powazekii), and viral encephalitis (alphaviruses, e.g., Venezuelan equine encephalitis; eastern equine encephalitis; western equine encephalitis); all of which are currently classified as Category B agents; and Nipan virus and hantaviruses, which are currently classified as Category C agents. In addition, other organisms, which are so classified or differently classified, may be identified and/or used for such a purpose in the future. It will be readily understood that the viral vectors and other constructs described herein are useful to deliver antigens from these organisms, viruses, their toxins or other by-products, which will prevent and/or treat infection or other adverse reactions with these biological agents.
The vectors of the invention can be used to deliver immunogens. In rheumatoid arthritis (RA), several specific variable regions of T-cell receptors (TCRs) which are involved in the disease have been characterized. These TCRs include V 3, V 14, and V 17. Thus, delivery of a nucleic acid sequence that encodes at least one of these polypeptides will elicit an immune response that will target T cells involved in RA. In multiple sclerosis (MS), several specific variable regions of TCRs which are involved in the disease have been characterized. These TCRs include V 7 and V 10. Thus, delivery of a nucleic acid sequence that encodes at least one of these polypeptides will elicit an immune response that will target T cells involved in MS. In scleroderma, several specific variable regions of TCRs which are involved in the disease have been characterized. These TCRs include V 6, V 8, V 14, V 3 C, V 7, V 14, V 15, V 16, V 28 and V 12. Thus, delivery of a nucleic acid molecule that encodes at least one of these polypeptides will elicit an immune response that will target T cells involved in scleroderma.
Other useful products include an "anti-pathogen construct" which is a protein, peptide, or other molecule encoded by a nucleic acid sequence carried on a viral vector as described herein, which is capable of providing passive immunity against the selected pathogenic agent or a cross-reactive strain of the pathogenic agent. In one embodiment, the anti-pathogen construct is a neutralizing antibody construct against the pathogenic agent, e.g., a virus, bacterium, fungus, or a pathogenic toxin of said agent (e.g., anthrax toxin). Examples of such pathogens are provided herein. As used herein, a "neutralizing antibody" is an antibody which defends a cell from an antigen or infectious body by inhibiting or neutralizing its biological effect. In one embodiment, "neutralizes" and grammatical variations thereof, refer to an activity of an antibody that prevents entry or translocation of the pathogen into the cytoplasm of a cell susceptible to infection. As used herein a
"neutralizing antibody construct" includes a full-length antibody (an immunoglobulin molecule), as well as antibody fragments or artificial constructs which have the ability to inhibit or neutralize an antigen or infectious agent. These antibody fragments or artificial constructs may include a single chain antibody, a Fab fragment, a univalent antibody, or an immunoadhesin. The neutralizing antibody construct may be a monoclonal antibody, a "humanized" antibody, a polyclonal antibody, or another suitable construct. An
"immunoglobulin molecule" is a protein containing the immunologically-active portions of an immunoglobulin heavy chain and immunoglobulin light chain covalently coupled together and capable of specifically combining with an antigen. Immunoglobulin molecules are of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., IgGl , IgG2, IgG3, IgG4, IgAl and IgA2) or subclass. The terms "antibody" and "immunoglobulin" may be used interchangeably herein. An "immunoglobulin heavy chain" is a polypeptide that contains at least a portion of the antigen binding domain of an immunoglobulin and at least a portion of a variable region of an immunoglobulin heavy chain or at least a portion of a constant region of an immunoglobulin heavy chain. Thus, the immunoglobulin derived heavy chain has significant regions of amino acid sequence homology with a member of the immunoglobulin gene superfamily. For example, the heavy chain in a Fab fragment is an immunoglobulin- derived heavy chain. An "immunoglobulin light chain" is a polypeptide that contains at least a portion of the antigen binding domain of an immunoglobulin and at least a portion of the variable region or at least a portion of a constant region of an immunoglobulin light chain. Thus, the immunoglobulin-derived light chain has significant regions of amino acid homology with a member of the immunoglobulin gene superfamily. An "immunoadhesin" is a chimeric, antibody-like molecule that combines the functional domain of a binding protein, usually a receptor, ligand, or cell-adhesion molecule, with immunoglobulin constant domains, usually including the hinge and Fc regions. A ""fragment antigen-binding" (Fab) fragment" is a region on an antibody that binds to antigens. It is composed of one constant and one variable domain of each of the heavy and the light chain. With respect to immunoglobulins or antibodies as described herein, a fragment of an immunoglobulin coding sequence may be modified according to the methods described herein. Suitable fragments may include the coding region for one or more of, e.g., a heavy chain, a light chain, and/or fragments thereof such as the constant region of a heavy chain (CHI , CH2 and/or CH3) and/or or the constant region of a light chain. Alternatively, variable regions of a heavy chain or light chain may be modified. Examples of such fragments include, without limitation: Position (nt)
Region SEO ID NO: 14 SED ID NO: 15 SEO ID NO: 18
VH (variable region heavy chain) 1365-1750 1371-1756 1320-1705
CHI (constant region 1 heavy chain) 1752-2027 1758-2033 1707-1982
HCH23 (constant region 2-3 heavy
chain) 2028-2716 2034-2722 1983-2671
CL (constant region light chain) 3111-3415 3181-3485 3130-3434
3nbcl 17 light 2798-3095 2854-3165 2803-3114
Still other immunoglobulin coding regions may be modified.
EXPRESSION CASSETTE
For use in producing a viral vector (e.g., a recombinant (r) AAV), the expression cassette can be carried on any suitable vector, e.g., a plasmid, which is delivered to a
packaging host cell. "Suitable regulatory sequences" refer to nucleotide sequences located upstream (5' non-coding sequences), within, or downstream (3' non-coding sequences) of a coding sequence, and which influence the transcription, RNA processing or stability, or translation of the associated coding sequence. Regulatory sequences may include promoters, translation leader sequences, introns, polyadenylation recognition sequences, RNA
processing sites, effector binding sites and stem-loop structures. Suitable transfection
techniques and packaging host cells are known and/or can be readily designed by one of skill in the art.
Examples of constitutive promoters suitable for controlling expression of the
transgenes include, but are not limited to chicken β-actin (CB) promoter, human
cytomegalovirus (CMV) promoter, the early and late promoters of simian virus 40 (SV40), U6 promoter, metallothionein promoters, EFla promoter, ubiquitin promoter, hypoxanthine phosphoribosyl transferase (HPRT) promoter, dihydrofolate reductase (DHFR) promoter
(Scharfmann et al, Proc. Natl. Acad. Sci. USA 88:4626-4630 (1991), adenosine deaminase promoter, phosphoglycerol kinase (PGK) promoter, pyruvate kinase promoter
phosphoglycerol mutase promoter, the β-actin promoter (Lai et al., Proc. Natl. Acad. Sci.
USA 86: 10006-10010 (1989)), the long terminal repeats (LTR) of Moloney Leukemia Virus and other retroviruses, the thymidine kinase promoter of Herpes Simplex Virus and other constitutive promoters known to those of skill in the art. Examples of tissue- or cell- preferential promoters suitable for use in the present invention include, but are not limited to, endothelin-I (ET -I) and Flt-I, which are for endothelial cells, FoxJl (that targets ciliated cells), human thyroxine binding globulin (TBG) and alpha- 1 anti -trypsin (A1AT) for liver, troponin and T (TnT) for heart, clara cell 10 (CC10), surfactant protein C (SPC) and FoxJl for heart; synapsin, tyrosine hydroxylase, CaMKII (Ca2+/calmodulin-dependent protein kinase) for central nervous system/brain, insulin and elastase-I for pancrease, Ap2 and adiponector for adipocyte, desmin and MHC for muscle, and VMD for retina. Still others are known in the art.
Inducible promoters suitable for controlling expression of the transgene include promoters responsive to exogenous agents (e.g., pharmacological agents) or to physiological cues. These response elements include, but are not limited to a hypoxia response element (HRE) that binds HIF-Ia and β, a metal-ion response element such as described by Mayo et al. (1982, Cell 29:99-108); Brinster et al. (1982, Nature 296:39-42) and Searle et al. (1985, Mol. Cell. Biol. 5:1480-1489); or a heat shock response element such as described by Nouer et al. (in: Heat Shock Response, ed. Nouer, L., CRC, Boca Raton, Fla., ppI67-220, 1991).
Examples of regulatable promoters which are ligand-dependent transcription factor complexes that may be used in the invention include, without limitation, members of the nuclear receptor superfamily activated by their respective ligands (e.g., glucocorticoid, estrogen, progestin, retinoid, ecdysone, and analogs and mimetics thereof) and rTTA activated by tetracycline. In one aspect of the invention, the gene switch is an EcR-based gene switch. Examples of such systems include, without limitation, the systems described in US Patent Nos. 6,258,603, 7,045,315, U.S. Published Patent Application Nos.
2006/0014711, 2007/0161086, and International Published Application No. WO 01/70816. Examples of chimeric ecdysone receptor systems are described in U.S. Pat. No. 7,091,038, U.S. Published Patent Application Nos. 2002/0110861, 2004/0033600, 2004/0096942, 2005/0266457, and 2006/0100416, and International Published Application Nos. WO
01/70816, WO 02/066612, WO 02/066613, WO 02/066614, WO 02/066615, WO 02/29075, and WO 2005/108617, each of which is incorporated by reference in its entirety. An example of a non-steroidal ecdysone agonist-regulated system is the RheoSwitch® Mammalian Inducible Expression System (New England Biolabs, Ipswich, MA).
Still other promoter systems may include response elements including but not limited to a tetracycline (tet) response element (such as described by Gossen & Bujard (1992, Proc. Natl. Acad. Sci. USA 89:5547-551); or a hormone response element such as described by Lee et al. (1981, Nature 294:228-232); Hynes et al. (1981, Proc. Natl. Acad. Sci. USA 78:2038-2042); Klock et al. (1987, Nature 329:734-736); and Israel & Kaufman (1989, Nucl. Acids Res. 17:2589-2604) and other inducible promoters known in the art. Using such promoters, expression of the neutralizing antibody construct can be controlled, for example, by the Tet-on/off system (Gossen et al., 1995, Science 268:1766-9; Gossen et al., 1992, Proc. Natl. Acad. Sci. USA., 89(12):5547-51); the TetR-KRAB system (Urrutia R., 2003, Genome Biol., 4(10):231 ; Deuschle U et al., 1995, Mol Cell Biol. (4):1907-14); the mifepristone (RU486) regulatable system (Geneswitch; Wang Y et al., 1994, Proc. Natl. Acad. Sci. USA., 91 (17):8180-4; Schillinger et al., 2005, Proc. Natl. Acad. Sci. U S
A.102(39):13789-94); the humanized tamoxifen-dep regulatable system (Roscilli et al., 2002, Mol. Ther. 6(5):653-63). In one system, a gene switch is based on heterodimerization of FK506 binding protein (FKBP) with FKBP rapamycin associated protein (FRAP) and is regulated through rapamycin or its non-immunosuppressive analogs. Examples of such systems, include, without limitation, the ARGENT™ Transcriptional Technology (ARIAD Pharmaceuticals, Cambridge, Mass.) and the systems described in U.S. Pat. Nos. 6,015,709, 6,117,680, 6,479,653, 6,187,757, and 6,649,595, U.S. Publication No. 2002/0173474, U.S. Publication No. 200910100535, U.S. Patent No. 5,834,266, U.S. Patent No. 7,109,317, U.S. Patent No. 7,485,441, U.S.Patent No. 5,830,462, U.S. Patent No. 5,869,337, U.S. Patent No. 5,871,753, U.S. Patent No. 6,011,018, U.S. Patent No. 6,043,082, U.S. Patent No. 6,046,047, U.S. Patent No. 6,063,625, U.S. Patent No. 6,140,120, U.S. Patent No. 6,165,787, U.S. Patent No. 6,972,193, U.S. Patent No. 6,326,166, U.S. Patent No. 7,008,780, U.S. Patent No. 6,133,456, U.S. Patent No. 6,150,527, U.S. Patent No. 6,506,379, U.S. Patent No. 6,258,823, U.S. Patent No. 6,693,189, U.S. Patent No. 6,127,521, U.S. Patent No. 6,150,137, U.S. Patent No. 6,464,974, U.S. Patent No. 6,509,152, U.S. Patent No. 6,015,709, U.S. Patent No. 6,117,680, U.S. Patent No. 6,479,653, U.S. Patent No. 6,187,757, U.S. Patent No. 6,649,595, U.S. Patent No. 6,984,635, U.S. Patent No. 7,067,526, U.S. Patent No. 7,196,192, U.S. Patent No. 6,476,200, U.S. Patent No. 6,492,106, WO 94/18347, WO 96/20951, WO 96/06097, WO 97/31898, WO 96/41865, WO 98/02441, WO 95/33052, WO 99110508, WO 99110510, WO 99/36553, WO 99/41258,WO 01114387, ARGENT™ Regulated
Transcription Retrovirus Kit, Version 2.0 (9109102), and ARGENT™ Regulated
Transcription Plasmid Kit, Version 2.0 (9109/02), each of which is incorporated herein by reference in its entirety. The Ariad system is designed to be induced by rapamycin and analogs thereof referred to as "rapalogs". Examples of suitable rapamycins are provided in the documents listed above in connection with the description of the ARGENT™ system. In one embodiment, the molecule is rapamycin [e.g., marketed as apamune™ by Pfizer]. In another embodiment, a rapalog known as AP21967 [ARIAD] is used. Examples of these dimerizer molecules that can be used in the present invention include, but are not limited to rapamycin, FK506, FK1012 (a homodimer of FK506), rapamycin analogs ("rapalogs") which are readily prepared by chemical modifications of the natural product to add a "bump" that reduces or eliminates affinity for endogenous FKBP and/or FRAP. Examples of rapalogs include, but are not limited to such as AP26113 (Ariad), AP1510 (Amara, J.F., et al.,1997, Proc Natl Acad Sci USA, 94(20): 10618-23) AP22660, AP22594, AP21370, AP22594, AP23054, AP1855, AP1856, AP1701, AP1861, AP1692 and AP1889, with designed 'bumps' that minimize interactions with endogenous FKBP. Still other rapalogs may be selected, e.g., AP23573 [Merck].
In addition to the elements identified above for the expression cassette, the vector may also include conventional control elements which are operably linked to the coding sequence in a manner which permits transcription, translation and/or expression of the encoded product (e.g., a neutralizing antibody or a portion thereof) in a cell transfected with the plasmid vector or infected with the virus produced by the invention. As used herein, "operably linked" sequences include both expression control sequences that are contiguous with the gene of interest and expression control sequences that act in trans or at a distance to control the gene of interest.
The term "heterologous" when used with reference to a protein or a nucleic acid indicates that the protein or the nucleic acid comprises two or more sequences or subsequences which are not found in the same relationship to each other in nature. For instance, the nucleic acid is typically recombinantly produced, having two or more sequences from unrelated genes arranged to make a new functional nucleic acid. For example, in one embodiment, the nucleic acid has a promoter from one gene arranged to direct the expression of a coding sequence from a different gene. Thus, with reference to the coding sequence, the promoter is heterologous.
As exemplified herein, the vector may be a plasmid and/or a recombinant AAV viral vector. However, it will be readily understood that the expression cassettes containing nucleic acid sequences generated as described herein may be engineered onto any number of vectors including, other viral vectors such as baculovirus, adenovirus, retroviruses, and the like. Methods for generating and isolating AAVs suitable for use as vectors are known in the art. See generally, e.g., Grieger & Samulski, 2005, "Adeno-associated virus as a gene therapy vector: Vector development, production and clinical applications," Adv. Biochem.
Engin/Biotechnol. 99: 119-145; Buning et al, 2008, "Recent developments in adeno- associated virus vector technology," J. Gene Med. 10:717-733; and the references cited below, each of which is incorporated herein by reference in its entirety.
An adeno-associated virus (AAV) viral vector is an AAV DNase-resistant particle having an AAV protein capsid into which is packaged nucleic acid sequences for delivery to target cells. In one embodiment, the AAV sequences on the expression cassette comprise only minimal AAV sequences to avoid the risk of replication. In one embodiment, the minimal AAV sequences include the AAV inverted terminal repeat sequences (ITR). In one embodiment, the 5' ITR and the 3' ITR are the minimal AAV sequences required in cis in order to express a transgene encoded by a nucleic acid sequence packaged in the AAV capsid. Typically, the ITRs flank the modified coding sequence for a selected gene product. In one embodiment, the AAV vector contains AAV 5' and 3' ITRs, which may be of the same AAV origin as the capsid, or which may be of a different AAV origin (to produce an AAV pseudotype). In one embodiment, the coding sequences for the replication (rep) and/or capsid (cap) are removed from the AAV genome and supplied in trans or by a packaging cell line in order to generate the AAV vector.
An AAV capsid is composed of 60 capsid protein subunits, VP1, VP2, and VP3, that are arranged in an icosahedral symmetry in a ratio of approximately 1 :1 :10 to 1 : 1 :20, depending upon the selected AAV. The capsid type does play a role in tissue specificity. The sequences of a variety of AAV have been described, as have methods of generating vectors having the AAV capsids. Examples of AAV which may be selected as sources for capsids of AAV viral vectors (DNase resistant viral particles) include, e.g., AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV6.2, AAV7, AAV8, AAV9, rhlO, AAVrh64Rl, AAVrh64R2, rh8 [See, e.g., US Published Patent Application No. 2007-0036760-A1 ; US Published Patent Application No. 2009-0197338-A1 ; EP 1310571]. See also, WO
2003/042397 (AAV7 and other simian AAV), US Patent 7790449 and US Patent 7282199 (AAV8), WO 2005/033321 and US 7,906,111 (AAV9), and WO 2006/110689]. As yet to be discovered AAV, or a recombinant AAV based thereon, may be used as a source for the AAV capsid. These documents also describe other AAV which may be selected for generating AAV and are incorporated by reference. In some embodiments, an AAV cap for use in the viral vector can be generated by mutagenesis (i.e., by insertions, deletions, or substitutions) of one of the aforementioned AAV Caps or its encoding nucleic acid. In some embodiments, the AAV capsid is chimeric, comprising domains from two or three or four or more of the aforementioned AAV capsid proteins. In some embodiments, the AAV capsid is a mosaic of Vpl, Vp2, and Vp3 monomers from two or three different AAVs or recombinant AAVs. In some embodiments, an rAAV composition comprises more than one of the aforementioned Caps.
For packaging a transgene into virions, the IT s are the only AAV components required in cis in the same construct as the transgene. The cap and rep genes can be supplied in trans. Accordingly, DNA constructs can be designed so that the AAV ITRs flank the coding sequence, thus defining the region to be amplified and packaged - the only design constraint being the upper limit of the size of the DNA to be packaged (approximately 4.5 kb). Adeno-associated virus engineering and design choices that can be used to save space are known in the art.
The components required to be cultured in the host cell to package an AAV minigene in an AAV capsid may be provided to the host cell in trans. Alternatively, any one or more of the required components {e.g., minigene, rep sequences, cap sequences, and/or helper functions) may be provided by a stable host cell which has been engineered to contain one or more of the required components using methods known to those of skill in the art. Most suitably, such a stable host cell will contain the required component(s) under the control of an inducible promoter. However, the required component(s) may be under the control of a constitutive promoter. Examples of suitable inducible and constitutive promoters are provided herein, in the discussion of regulatory elements suitable for use with the transgene. In still another alternative, a selected stable host cell may contain selected component(s) under the control of a constitutive promoter and other selected component(s) under the control of one or more inducible promoters. For example, a stable host cell may be generated which is derived from 293 cells (which contain El helper functions under the control of a constitutive promoter), but which contains the rep and/or cap proteins under the control of inducible promoters. Still other stable host cells may be generated by one of skill in the art.
The minigene, rep sequences, cap sequences, and helper functions required for producing the rAAV of the invention may be delivered to the packaging host cell in the form of any genetic element which transfer the sequences carried thereon. The selected genetic element may be delivered by any suitable method, including those described herein. The methods used to construct any embodiment of this invention are known to those with skill in nucleic acid manipulation and include genetic engineering, recombinant engineering, and synthetic techniques. See, e.g., Sambrook et al, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor, NY. Similarly, methods of generating rAAV virions are well known and the selection of a suitable method is not a limitation on the present invention. See, e.g., K. Fisher et al, (1993) J. Virol, 70:520-532 and US Patent No. 5,478,745.
Unless otherwise specified, the AAV IT s, and other selected AAV components described herein, may be readily selected from among any AAV. Further, more than one AAV source may provide elements to an AAV vector. For example, as described above, a pseudotyped AAV may contain ITRs from a source which differs from the source of the AAV capsid. Additionally or alternatively, a chimeric AAV capsid may be utilized. Still other AAV components may be selected. Sources of such AAV sequences are described herein and may also be isolated or obtained from academic, commercial, or public sources {e.g., the American Type Culture Collection, Manassas, VA). Alternatively, the AAV sequences may be obtained through synthetic or other suitable means by reference to published sequences such as are available in the literature or in databases such as, e.g., GenBank®, PubMed®, or the like.
In one embodiment, the pharmaceutical compositions include a single vector containing an expression cassette comprising a modified ORF as described above. In another embodiment, the composition includes more than one vector, each containing one or more expression cassettes. Each expression cassette comprises a modified ORF. In another embodiment, the composition includes multiple viral vectors, each containing one or more expression cassettes as described herein.
The AAV vectors may be suspended in a physiologically compatible carrier for administration to a human or non-human mammalian patient. Suitable carriers may be readily selected by one of skill in the art in view of the route of delivery. For example, one suitable carrier includes saline, which may be formulated with a variety of buffering solutions {e.g., phosphate buffered saline). Other exemplary carriers include sterile saline, lactose, sucrose, calcium phosphate, gelatin, dextran, agar, pectin, peanut oil, sesame oil, and water. The selection of the carrier is not a limitation of the present invention. Optionally, the compositions of the invention may contain, in addition to the rAAV and carrier(s), other conventional pharmaceutical ingredients, such as preservatives, or chemical stabilizers. Suitable exemplary preservatives include chlorobutanol, potassium sorbate, sorbic acid, sulfur dioxide, propyl gallate, the parabens, ethyl vanillin, glycerin, phenol, and
parachlorophenol. Suitable chemical stabilizers include gelatin and albumin.
The following examples are illustrative only and are not a limitation on the invention described herein.
EXAM PLE 1 - MODI FICATION OF OPEN READI NG FRAM E (ORF) OF ANTI- H IV ANTI BODY
The ORF of an anti-SIV antibody which had previously been shown to express at unusually high levels in liver as compared to other tissue types and other ORFs. From this observation, the study described herein was designed. Using an anti-HIV antibody coding sequence as a base sequence for proof-of-principal, 12 alternative synonymous codon modified ORFs were generated using different methods by DNA2.0 [Menlo Park, CA] . These sequences are provided in Figure 1 , which is incorporated by reference herein. The ORF for the anti-HIV antibody which served as the base ORF in the study described herein had previously been altered in our laboratory and was observed to preferentially express at very high levels in liver. The base sequence, which served as the control, was modified using the coding frequencies for human, as provided by http://www.kazusa.or.jp/codon/cgi- bin/showcodon.cgi?species:=9606 (Table 2). Additional modifications were made by hand to remove restriction sites and other non-desirable features (e.g., CpG islands).
The following Table 18 provides a comparison of the identity of the modified ORFs generated and studied herein. The sequences of the ORFs are contained in SEQ ID NOs: 1 - 12 and 30. An alignment of the sequences is provided in Figs. lA-1 J.
Table 18 - Comparison of Identity of Modified ORFs
Figure imgf000044_0001
These ORFs were engineered into a plasmid construct (F2A) and expression levels were assessed in HEK 293 cells. The sequences of these plasmids are provided in the attached FIG. 5 (SEQ ID NOs: 13-29), which is incorporated by reference herein.
The data in Table 19 provides the results on an in vitro assessment of the plasmid constructs in HEK 293 cells. As shown in Fig. 2, expression of the gene under the control of human cytomegalovirus promoter (CMV(first bar)) or a CMV promoter with a commercially available enhancer (Promega intron, PI)(third bar) were assessed in HEK 293 cells at 72 hours post-transfection. Cells were transfected with 2 x 1010 GC/per mouse and expression levels were assessed at day 50. The pZac is an empty vector carrying only the promoter and enhancer. F2A is a plasmid containing the "base" or parental anti-HIV antibody ORF under the control of the CMV-IE promoter. Mini-C is similar to the F2a, in that it contains the "base" or parental anti-HIV antibody ORF under the control of the CMV-IE promoter, but it further contains a 5 'UTR.
Protein levels determined by ELISA for 2-3 transfections (HEK) approximately 72 hours (three days) after the last transfection. Table 19
Figure imgf000045_0001
Open squares indicate that the study was not done to date.
As shown in Table 19, in the 293 cells, there were significant differences in expression levels for all modified genes expressed from the CMV promoter, with the
ORF26, IA U and IAM U constructs showing the strongest expression levels. There were also significant differences in in vitro expression levels for all modified genes expressed under the CMV promoter with the enhancer (CMV-IE). These data show that none of the modified constructs provide expression levels significantly higher than the base vector. With the promoter-enhancer, ORF 35 show the strongest expression levels followed by ORFl 1.
The plasmids carrying the genes described above expressed under the CMV-PI promoter/enhancer were packaged into AAV8 capsids using published methods and the resulting AAV.CMV-lE.modified genes were expressed in a non-secretory tissue (muscle) and a secretory tissue (lung). Except where otherwise specified, animals (RAG KO) were delivered 2 x 1010 genomic particles/mL. For those animals injected im, serum levels of protein were determined on day 50 post-injection by ELISA (Fig. 2 (middle bars)). For those animals for which the constructs were delivered by nasal installation, protein levels in bronchial lavage were determined by ELISA seven days following installation. Table 20 provides the results. Table 20
Figure imgf000046_0001
Open squares indicate that the study was not done to date.
* Vector 1 x 1010
** Day 35, rather than day 50
With the exception of AAV8 vectors carrying ORF2 and ORF11 which were approximately the same as the parental gene, the tested constructs outperformed the vector expressing the parental gene in muscle. The muscle expression levels observed for the ORF 1 vector was about the same as for the vector carrying the parental gene, but at half the dose. The highest expression levels for muscle were observed for ORF35 and ORF39, which were both approximately four times the expression level of the parental gene.
In respiratory epithelium, the expression levels observed for vector carrying the parental gene were higher than those for the vectors carrying the other modified genes. Significant variations in expression levels were observed, with the vectors carrying IA U, ORF40 and ORF2 expressing at higher levels that the other vectors with the exception of the vector carrying the parental gene.
These observations demonstrate that in vitro assessment of codon optimization is not predictive of expression levels in all tissues. As seen above, in the HEK 293 cells, none of the codon modified genes tested expressed at a higher level than the parental gene. It is possible that the derivation of the 293 cell line from human embryonic kidney cells would be predictive of expression levels in kidney. While in this example, the results observed in 293 cells are consistent with the expression levels observed in lung, significantly different expression results were observed in muscle. This suggests that there are tissue-specific codon patterns and that one can select an algorithmic schema for modification of a selected gene which will preferentially enhance its expression in a selected target tissue.
EXAMPLE 2
A further study was conducted using, 2xl010 GC/mouse of AAV8 containing modified transgenes were injected IV for liver expression into RAG KO mice (n=5 mice per construct) as described above. Expression of circulating antibody in serum was monitored by ELISA for 56 days. The results are shown the following Table 21 and demonstrate significant differences in expression in liver between the modified open reading frames. For example, the ORF2, ORF11, ORF26, ORF35 and IAU constructs consistently expressed at a higher level in liver than the 5' UTR construct, which served as a control. ORF39 expressed slightly higher in liver than the control at longer time periods, while ORF 42, ORF28 and ORF 1 expressed at a similar level to the control. The LAM construct showed consistently low levels of expression in liver. Table 21
Figure imgf000048_0001
Figure imgf000048_0002
5'UTR (mini C)
ORF 0 ORF42 IAU 1AM (Control)
Average stdev. average stdev. average stdev. average stdev. average stdev.
Day 0 0.00 0.00 0.00 0.00 0.00
Day 7 24.27 9.77 39.76 21.52 97.67 48.61 12.20 4.71 69.92 50.36
Day
51.19 20.44 95.10 49.91 265.20 108.20 16.36 8.31 104.01 77.79 14
Day
62.95 25.19 88.78 49.39 330.53 162.77 15.54 6.32 104.33 64.62 21
Day
62.13 23.99 121.84 63.78 485.02 212.38 16.88 7.47 178.63 98.22 28
Day
53.33 23.81 141.57 78.12 303.62 112.68 11.24 5.86 108.76 61.08 35
Day
60.89 27.56 92.60 56.49 369.47 144.21 10.88 5.07 107.73 44.34 42
Day
53.40 23.19 96.15 61.31 320.29 164.55 16.89 8.70 118.86 53.48 49
Day
53.47 21.99 105.53 64.25 377.35 158.09 12.24 6.49 93.13 37.43 56
EXAMPLE 3
AAV8 containing one of two modified constructs, 10A (SEQ ID NO: 32) or 201 5 (SEQ ID NO: 31), were injected into mice as described above (lxlO11 GC/mouse).
Expression in muscle and liver was determined by ELISA. FIG. 6 is a graph showing the expression of the 201 construct in muscle (bottom line) and liver (top line) of mice versus time post transduction. 5 mice per group were injected at the indicated dosages (lxl O10 or lxl O11 GC/per mouse). Concentrations were determined by ELISA. Capture accomplished 10 by binding to SIV mac251 gpl20; detection by Fc chain antibody (IgGl) conjugated with
biotin, followed by HRP-streptavidin.
FIG. 7 is a graph showing the expression of the 10A construct in muscle (bottom line) and liver (top line) of mice versus time post transduction. 5 mice per group were injected at the dosage of lxl O11 GC/per mouse. CMV promoter was used for IM injections; 15 TBG promoter was used for IV injections.
A comparison of these two figures shows that, in both muscle and liver, the 201 construct expresses levels greater than 10 fold as compared to the 10A construct.
The 3bncl 17 antibody coding sequence was optimized using the codon frequency of human (Table 2) or 201 (Table 16) manually. The codon frequencies for the final sequences are shown in tables 22 (human) and 23 (201) below. AAV8 constructs utilizing the TBM promoter and incorporating 3bnCl 17/hum (SEQ ID NO: 34) or 3bnCl 17/201 (SEQ ID NO: 33) sequence were injected intravenously into mice at a dosage of lxlO11 GC/per mouse. Expression in liver is shown in Fig. 8. Expression of the 3bnCl 17/201 in liver was -2.5 to over 3 times greater than expression using the human codon frequency optimized sequence.
Table 22
Sequence Codon (frequency: per thousand)
3bnC117/HUM u uu 14.3 UCU 14.3 UAU 14.3 UGU 4.1
u uc 20.4 UCC 22.4 UAC 28.5 UGC 18.3
U UA 4.1 UCA 12.2 UAA 0 UGA 0
U UG 6.1 UCG 8.1 UAG 0 UGG 26.5
CU U 6.1 CCU 14.3 CAU 4.1 CGU 8.1
CUC 14.3 CCC 24.4 CAC 12.2 CGC 2
CUA 4.1 CCA 22.4 CAA 12.2 CGA 10.2
CUG 42.8 CCG 6.1 CAG 46.8 CGG 10.2
AUU 8.1 ACU 8.1 AAU 14.3 AGU 10.2
AUC 18.3 ACC 34.6 AAC 28.5 AGC 32.6
AUA 0 ACA 14.3 AAA 20.4 AGA 14.3
AUG 12.2 ACG 8.1 AAG 34.6 AGG 4.1
GUU 2 GCU 2 GAU 12.2 GGU 4.1
GUC 40.7 GCC 20.4 GAC 36.7 GGC 26.5
GUA 2 GCA 18.3 GAA 14.3 GGA 28.5
GUG 36.7 GCG 8.1 GAG 26.5 GGG 24.4
Table 23
Sequence Codon (frequency: per thousand)
3bnC117/201 U UU 6.1 UCU 6.1 UAU 6.1 UGU 10.2
u uc 32.7 UCC 20.4 UAC 34.7 UGC 12.2
U UA 0 UCA 12.2 UAA 0 UGA 0
U UG 0 UCG 2 UAG 0 UGG 28.6
CUU CCU 18.4 CAU 4.1 CGU 2 CUC CCC 20.4 CAC 12.2 CGC 4.1 CUA CCA 28.6 CAA 0 CGA 4.1 CUG CCG 0 CAG 59.2 CGG 24.5 AUU 6.1 ACU 12.2 AAU 8.2 AGU 8.2
AUC 18.4 ACC 32.7 AAC 32.7 AGC 46.9
AUA 0 ACA 16.3 AAA 18.4 AGA 4.1
AUG 10.2 ACG 2 AAG 38.8 AGG 8.2
GUU 0 GCU 4.1 GAU 34.7 GGU 0
GUC 18.4 GCC 34.7 GAC 14.3 GGC 28.6
GUA 0 GCA 4.1 GAA 12.2 GGA 44.9
GUG 67.3 GCG 2 GAG 30.6 GGG 16.3
Table for Free Text in Feature <220>
Figure imgf000051_0001
24 Artificial sequence synthetic sequence
25 Artificial sequence synthetic sequence
26 Artificial sequence synthetic sequence
27 Artificial sequence synthetic sequence
28 Artificial sequence synthetic sequence
29 Artificial sequence synthetic sequence
30 Artificial sequence synthetic sequence
31 Artificial sequence synthetic sequence
32 Artificial sequence synthetic sequence
33 Artificial sequence synthetic sequence
34 Artificial sequence synthetic sequence
This application contains sequences and a sequence listing, filed herewith as a text file named Z6688PCT_SEQ_LIST_042914_ST25. All publications, patents, and patent applications cited in this application are hereby incorporated by reference in their entireties as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications can be made thereto without departing from the spirit or scope of the appended claims.

Claims

CLAIMS:
1. A method for improving expression of a selected gene product in a selected type of target tissue within a selected species, said method comprising: constructing an expression cassette comprising a coding sequence for a selected gene product generated with a selected codon frequency of Table 3, Table 4, Table 5, Table 6, Table 7, Table 8, Table 9, Table 10, Table 11, Table 12, Table 16, or Table 17, or a codon frequency within 10% of any one of these tables.
2. The method according to claim 1, wherein the target tissue is selected from liver, skeletal muscle, and respiratory epithelium.
3. The method according to claim 1 or claim 2, wherein the target tissue is skeletal muscle and the selected codon frequency is Table 5, Table 6, or a codon frequency within about 10% thereof.
4. The method according to claim 1 or claim 2, wherein the target tissue is liver and the selected codon frequency is Table 9, Table 10, Table 11 , or a codon frequency within about 10% of Table 9, Table 10, or Table 11.
5. The method according to any one of claims 1 to 5, wherein the target tissue is respiratory epithelium and the selected codon frequency is Table 16 or a codon frequency within about 10% of Table 16.
6. A synthetic nucleic acid sequence having codons optimized for expression in a selected tissue, said synthetic nucleic acid sequence generated according to a method of claim 1.
7. A recombinant vector comprising an expression cassette containing a synthetic nucleic acid sequence according to claim 6.
8 An expression cassette comprising an open reading frame (ORF) for an antibody construct under the control of regulatory sequences which direct expression of the product in a muscle cell, which ORF has been modified to preferentially increase expression levels in muscle, wherein the modified ORF has a sequence selected from the group consisting of ORFl (SEQ ID NO: 9), ORF 2 (SEQ ID NO: 8), ORF11 (SEQ ID NO: 7), ORF26 (SEQ ID NO: 6), ORF 28 (SEQ ID NO: 5), ORF 30 (SEQ ID NO: 4), ORF35 (SEQ ID NO: 3), ORF39 (SEQ ID NO: 2), ORF40 (SEQ ID NO: 1), ORF42 (SEQ ID NO: 30), IA (SEQ ID NO: 10), 201 (SEQ ID NO: 31) and IAM (SEQ ID NO: 11).
9. The expression cassette according to claim 8, wherein modified ORF is selected from ORF35 and ORF39.
10. The expression cassette according to claim 8, wherein the modified
ORF is ORF40.
11. The expression cassette according to claim 8, wherein the modified
ORF is selected from ORF26 and ORF30.
12. The expression cassette according to claim 8, wherein the modified ORF is selected from ORF2, ORF 11, ORF26, ORF35 and ORFIAU.
13. The expression cassette according to claim 8, wherein the regulatory sequences comprise a tissue specific promoter.
14. A vector comprising the expression cassette according to claim 8 and other genetic elements.
15. The vector according to claim 14, wherein said vector is a recombinant adeno-associated virus (AAV) having an AAV capsid in which the expression cassette is packaged.
16. A recombinant AAV comprising an AAV8 capsid and an expression cassette for an anti-HIV antibody, wherein the expression cassette is adapted for expression in a selected target tissue, said expression cassette comprising a modified ORF having a sequence selected from the group consisting of ORF 1 (SEQ ID NO: 9), ORF 2 (SEQ ID NO: 8), ORF11 (SEQ ID NO: 7), ORF26 (SEQ ID NO: 6), ORF 28 (SEQ ID NO: 5), ORF 30 (SEQ ID NO: 4), ORF35 (SEQ ID NO: 3), ORF39 (SEQ ID NO: 2), ORF40 (SEQ ID NO: 1), ORF42 (SEQ ID NO: 30), IA (SEQ ID NO: 10), 201 (SEQ ID NO: 31) and IAM (SEQ ID NO: 11).
17. An expression cassette comprising an open reading frame (ORF) for an antibody construct under the control of regulatory sequences which direct expression of the product in cell, which ORF has been modified to preferentially increase expression levels in a target tissue cells, wherein the modified ORF is characterized by a triplet frequency of any one of Tables 3 to 12.
18. The expression cassette according to claim 17, wherein the cell is a liver cell.
19. A vector comprising the expression cassette according to claim 17.
20. The vector according to claim 19, wherein said vector is a recombinant adeno-associated virus (AAV) having an AAV capsid in which the expression cassette is packaged.
21. The vector according to claim 19, wherein the expression cassette comprises AAV inverted terminal repeat (IT ) sequences flanking the modified ORF.
22. The vector according to claim 19, wherein the ITRs are from a different AAV than the AAV donor for the capsid.
23. An expression cassette comprising an open reading frame (ORF) for an antibody construct under the control of regulatory sequences which direct expression of the product in cell, which ORF has been modified to preferentially increase expression levels in non-secretory cells, wherein the modified ORF is characterized by a triplet frequency of Table 16 or or Table 17.
24. A pharmaceutical composition comprising a vector which comprises more expression cassettes of claim 23.
25. A composition comprising multiple vectors, wherein each vector comprises an expression cassette of claim 23 other genetic elements.
PCT/US2014/035880 2013-04-29 2014-04-29 Tissue preferential codon modified expression cassettes, vectors containing same, and use thereof WO2015012924A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US14/787,622 US9719106B2 (en) 2013-04-29 2014-04-29 Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof
US15/627,805 US10647998B2 (en) 2013-04-29 2017-06-20 Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361817110P 2013-04-29 2013-04-29
US61/817,110 2013-04-29

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/787,622 A-371-Of-International US9719106B2 (en) 2013-04-29 2014-04-29 Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof
US15/627,805 Continuation US10647998B2 (en) 2013-04-29 2017-06-20 Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof

Publications (2)

Publication Number Publication Date
WO2015012924A2 true WO2015012924A2 (en) 2015-01-29
WO2015012924A3 WO2015012924A3 (en) 2015-03-19

Family

ID=52393936

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/035880 WO2015012924A2 (en) 2013-04-29 2014-04-29 Tissue preferential codon modified expression cassettes, vectors containing same, and use thereof

Country Status (2)

Country Link
US (2) US9719106B2 (en)
WO (1) WO2015012924A2 (en)

Cited By (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017024198A1 (en) 2015-08-06 2017-02-09 The Trustees Of The University Of Pennsylvania Glp-1 and use thereof in compositions for treating metabolic diseases
WO2017040524A1 (en) 2015-08-31 2017-03-09 The Trustees Of The University Of Pennsylvania Aav-epo for treating companion animals
WO2017055872A1 (en) * 2015-09-30 2017-04-06 Ucl Business Plc Diabetes gene therapy
WO2017075119A1 (en) 2015-10-28 2017-05-04 The Trustees Of The Univeresity Of Pennsylvania Intrathecal administration of adeno-associated-viral vectors for gene therapy
WO2017180861A1 (en) 2016-04-15 2017-10-19 The Trustees Of The University Of Pennsulvania Gene therapy for treating hemophilia b
WO2017180857A1 (en) 2016-04-15 2017-10-19 The Trustees Of The University Of Pennsylvania Gene therapy for treating hemophilia a
WO2018011572A1 (en) * 2016-07-12 2018-01-18 The University Of Manchester Gene therapy
WO2018126116A1 (en) 2016-12-30 2018-07-05 The Trustees Of The University Of Pennsylvania Gene therapy for treating wilson's disease
WO2018160585A2 (en) 2017-02-28 2018-09-07 The Trustees Of The University Of Pennsylvania Compositions useful in treatment of spinal muscular atrophy
WO2018160582A1 (en) 2017-02-28 2018-09-07 The Trustees Of The University Of Pennsylvania Adeno-associated virus (aav) clade f vector and uses therefor
WO2018160573A1 (en) 2017-02-28 2018-09-07 The Trustees Of The University Of Pennsylvania Influenza vaccines based on aav vectors
US10138295B2 (en) 2014-05-13 2018-11-27 The Trustees Of The University Of Pennsylvania Compositions comprising AAV expressing dual antibody constructs and uses thereof
WO2018218359A1 (en) 2017-05-31 2018-12-06 The Trustees Of The University Of Pennsylvania Gene therapy for treating peroxisomal disorders
WO2019014061A1 (en) 2017-07-12 2019-01-17 Dow Global Technologies, Llc Compositions and methods for remediation of sulfate reducing prokaryotes
US10335466B2 (en) 2014-11-05 2019-07-02 Voyager Therapeutics, Inc. AADC polynucleotides for the treatment of parkinson's disease
US10413598B2 (en) 2014-11-12 2019-09-17 Ucl Business Plc Factor IX gene therapy
US10570395B2 (en) 2014-11-14 2020-02-25 Voyager Therapeutics, Inc. Modulatory polynucleotides
US10577627B2 (en) 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
US10584337B2 (en) 2016-05-18 2020-03-10 Voyager Therapeutics, Inc. Modulatory polynucleotides
US10597660B2 (en) 2014-11-14 2020-03-24 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
WO2020072354A1 (en) 2018-10-01 2020-04-09 The Trustees Of The University Of Pennsylvania Compositions useful for treating gm1 gangliosidosis
WO2020176562A1 (en) 2019-02-26 2020-09-03 The Trustees Of The University Of Pennsylvania Compositions useful in treatment of krabbe disease
US10780182B2 (en) 2014-04-25 2020-09-22 The Trustees Of The University Of Pennsylvania Methods and compositions for treating metastatic breast cancer and other cancers in the brain
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
US10988519B2 (en) 2015-09-24 2021-04-27 The Trustees Of The University Of Pennsylvania Composition and method for treating complement-mediated disease
WO2021155337A1 (en) 2020-02-02 2021-08-05 The Trustees Of The University Of Pennsylvania Compositions useful for treating gm1 gangliosidosis
US11103596B2 (en) 2015-05-11 2021-08-31 Ucl Business Plc Fabry disease gene therapy
WO2021231443A1 (en) 2020-05-12 2021-11-18 The Trustees Of The University Of Pennsylvania Compositions useful in treatment of krabbe disease
US11197936B2 (en) 2016-07-08 2021-12-14 The Trustees Of The University Of Pennsylvania Methods and compositions for treatment of disorders and diseases involving RDH12
WO2022036220A1 (en) 2020-08-14 2022-02-17 The Trustees Of The University Of Pennsylvania Novel aav capsids and compositions containing same
WO2022046815A1 (en) 2020-08-24 2022-03-03 The Trustees Of The University Of Pennsylvania Viral vectors encoding glp-1 receptor agonist fusions and uses thereof in treating metabolic diseases
US11273227B2 (en) 2015-10-09 2022-03-15 The Trustees Of The University Of Pennsylvania Compositions and methods useful in treating Stargardt's disease and other ocular disorders
WO2022060916A1 (en) * 2020-09-15 2022-03-24 Regenxbio Inc. Vectorized antibodies for anti-viral therapy
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
US11298041B2 (en) 2016-08-30 2022-04-12 The Regents Of The University Of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
WO2022076803A1 (en) 2020-10-09 2022-04-14 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of fabry disease
WO2022076582A1 (en) 2020-10-07 2022-04-14 Regenxbio Inc. Gene therapy for ocular manifestations of cln2 disease
WO2022094180A1 (en) 2020-10-29 2022-05-05 The Trustees Of The University Of Pennsylvania Aav capsids and compositions containing same
US11382941B2 (en) 2016-12-30 2022-07-12 The Trustees Of The University Of Pennsylvania Gene therapy for treating Phenylketonuria
WO2022165313A1 (en) 2021-02-01 2022-08-04 Regenxbio Inc. Gene therapy for neuronal ceroid lipofuscinoses
US11434502B2 (en) 2017-10-16 2022-09-06 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (ALS)
WO2022232267A1 (en) 2021-04-27 2022-11-03 The Trustees Of The University Of Pennsylvania Porcine-derived adeno-associated virus capsids and uses thereof
US11497576B2 (en) 2017-07-17 2022-11-15 Voyager Therapeutics, Inc. Trajectory array guide system
US11512327B2 (en) 2017-08-03 2022-11-29 Voyager Therapeutics, Inc. Compositions and methods for delivery of AAV
US11535665B2 (en) 2015-05-13 2022-12-27 The Trustees Of The University Of Pennsylvania AAV-mediated expression of anti-influenza antibodies and methods of use thereof
US11535866B2 (en) 2017-02-01 2022-12-27 The Trustees Of The University Of Pennsylvania Gene therapy for treating citrullenemia
US11564996B2 (en) 2017-03-01 2023-01-31 The Trustees Of The University Of Pennsylvania Gene therapy for ocular disorders
US11591614B2 (en) 2017-05-11 2023-02-28 The Trustees Of The University Of Pennsylvania Gene therapy for ceroid lipofuscinoses
US11603542B2 (en) 2017-05-05 2023-03-14 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
WO2023056399A1 (en) 2021-10-02 2023-04-06 The Trustees Of The University Of Pennsylvania Novel aav capsids and compositions containing same
JP2023515711A (en) * 2020-04-27 2023-04-13 ユニヴァーシティ オブ アイオワ リサーチ ファウンデーション Compositions and methods for the treatment of cystic fibrosis
US11629198B2 (en) 2017-12-05 2023-04-18 The Trustees Of The University Of Pennsylvania Fusion proteins and antibodies targeting human red blood cell antigens
CN116103320A (en) * 2022-11-16 2023-05-12 深圳万可森生物科技有限公司 Optimization of encoding gene of rhabdovirus G2 protein of weever
WO2023102517A1 (en) 2021-12-02 2023-06-08 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of fabry disease
WO2023125481A1 (en) 2021-12-28 2023-07-06 成都弘基生物科技有限公司 Modified aav capsid protein and use thereof
US11697825B2 (en) 2014-12-12 2023-07-11 Voyager Therapeutics, Inc. Compositions and methods for the production of scAAV
WO2023147304A1 (en) 2022-01-25 2023-08-03 The Trustees Of The University Of Pennsylvania Aav capsids for improved heart transduction and detargeting of liver
US11752181B2 (en) 2017-05-05 2023-09-12 Voyager Therapeutics, Inc. Compositions and methods of treating Huntington's disease
US11759506B2 (en) 2017-06-15 2023-09-19 Voyager Therapeutics, Inc. AADC polynucleotides for the treatment of Parkinson's disease
WO2023240236A1 (en) 2022-06-10 2023-12-14 Voyager Therapeutics, Inc. Compositions and methods for the treatment of spinal muscular atrophy related disorders
US11879133B2 (en) 2017-04-24 2024-01-23 The Trustees Of The University Of Pennsylvania Gene therapy for ocular disorders
US11883470B2 (en) 2016-07-25 2024-01-30 The Trustees Of The University Of Pennsylvania Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof
US11931375B2 (en) 2017-10-16 2024-03-19 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (ALS)
WO2024069549A1 (en) 2022-09-29 2024-04-04 Touchlight Aquaculture Limited Vaccine construct and uses thereof
US11951121B2 (en) 2016-05-18 2024-04-09 Voyager Therapeutics, Inc. Compositions and methods for treating Huntington's disease
EP4114439A4 (en) * 2020-03-03 2024-04-17 American Gene Technologies International Inc. On demand expression of exogenous factors in lymphocytes to treat hiv
WO2024105638A1 (en) 2022-11-18 2024-05-23 Jcr Pharmaceuticals Co., Ltd. Recombinant aav vectors and methods for treatment of hunter syndrome
US12090200B2 (en) 2016-02-08 2024-09-17 American Gene Technologies International Inc. Methods of producing cells resistant to HIV infection
US12146150B2 (en) 2022-09-13 2024-11-19 Voyager Therapeutics, Inc. Rescue of central and peripheral neurological phenotype of friedreich's ataxia by intravenous delivery

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015012924A2 (en) * 2013-04-29 2015-01-29 The Trustees Of The University Of Pennsylvania Tissue preferential codon modified expression cassettes, vectors containing same, and use thereof
JP6741590B2 (en) 2014-04-25 2020-08-19 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア LDLR variants for lowering cholesterol levels and their use in compositions
ES2921450T3 (en) 2015-12-11 2022-08-25 Univ Pennsylvania Gene therapy for the treatment of familial hypercholesterolemia
AU2017313917B2 (en) 2016-08-18 2023-12-21 The Regents Of The University Of California CRISPR-Cas genome engineering via a modular AAV delivery system
CA3051011A1 (en) 2017-02-20 2018-08-23 The Trustees Of The University Of Pennsylvania Gene therapy for treating familial hypercholesterolemia
SG11202100139VA (en) 2018-07-17 2021-02-25 Neuromyon Inc Treatment of neuropathy with dna constructs expressing igf-1 isoforms
WO2020160508A1 (en) 2019-01-31 2020-08-06 Oregon Health & Science University Methods for using transcription-dependent directed evolution of aav capsids

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4886876A (en) 1983-03-31 1989-12-12 Scripps Clinic And Research Foundation Factor VIII coagulant polypeptides
EP0162067B1 (en) 1983-10-28 1992-07-15 Genetics Institute, Inc. Production of factor viii and related products
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US5045455A (en) 1984-01-12 1991-09-03 Chiron Corporation Factor VIII:C cDNA cloning and expression
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
IL74909A (en) 1984-04-20 1992-01-15 Genentech Inc Preparation of functional human factor viii and dna sequences,expression vectors,transformed microorganisms and cell lines used therein
EP0182448A3 (en) 1984-08-24 1987-10-28 Genetics Institute, Inc. Production of factor viii and related products
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
FI98829C (en) 1986-01-27 1997-08-25 Chiron Corp Process for Preparation of Recombinant Protein Complex with Human Factor VIII: C Activity
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US5451521A (en) 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US5149637A (en) 1987-04-06 1992-09-22 Scripps Clinic & Research Foundation Recombinant Factor VIIIC fragments
US5171844A (en) 1987-06-12 1992-12-15 Gist-Brocades N.W. Proteins with factor viii activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
FR2619314B1 (en) 1987-08-11 1990-06-15 Transgene Sa FACTOR VIII ANALOG, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
US5004803A (en) 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
US5066886A (en) 1989-10-31 1991-11-19 Carpenter Technology Corporation Thermally responsive article, method of making same, and a device incorporataing said article
DE69032043T2 (en) 1989-11-17 1998-06-04 Chiron Corp PROTEIN COMPLEXES WITH FACTOR VIII: C ACTIVITY AND THEIR PRODUCTION
SE465222C5 (en) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab A recombinant human factor VIII derivative and process for its preparation
US5661008A (en) 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
SE468050C (en) 1991-03-15 1998-04-27 Pharmacia & Upjohn Ab Recombinant human factor VIII derivative
CA2078721A1 (en) 1991-09-24 1993-03-25 Hiroshi Yonemura Process for preparing human coagulation factor viii protein complex
WO1994011013A1 (en) 1992-11-13 1994-05-26 Duke University Chimeric blood coagulation proteins
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
WO1994018347A1 (en) 1993-02-05 1994-08-18 Laporte Group Australia Limited A slag defoaming composite
US5869337A (en) 1993-02-12 1999-02-09 President And Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
US6063625A (en) 1993-02-12 2000-05-16 Board Of Trustees Of Leland S, Stanford, Jr. University Regulated transcription of targeted genes and other biological events
US5834266A (en) 1993-02-12 1998-11-10 President & Fellows Of Harvard College Regulated apoptosis
PL310327A1 (en) 1993-02-12 1995-12-11 Univ Leland Stanford Junior Adjustable transcription of target genes and other biological processes
US6972193B1 (en) 1993-02-12 2005-12-06 Board Of Trustees Of Leland Stanford Junior University Regulated transcription of targeted genes and other biological events
US5830462A (en) 1993-02-12 1998-11-03 President & Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
US20020173474A1 (en) 1993-02-12 2002-11-21 President And Fellows Of Harvard College Methods & materials involving dimerization-mediated regulation of biological events
EP0874057B1 (en) 1993-06-10 2004-07-28 Bayer Corporation Vector and mammalian cell line having improved productivity
US6150137A (en) 1994-05-27 2000-11-21 Ariad Pharmaceuticals, Inc. Immunosuppressant target proteins
US6476200B1 (en) 1994-06-27 2002-11-05 The Johns Hopkins University Mammalian proteins that bind to FKBP12 in a rapamycin-dependent fashion
US6492106B1 (en) 1994-06-27 2002-12-10 The Johns Hopkins University Mammalian proteins that bind to FKBP12 in a rapamycin-dependent fashion
WO1996006097A1 (en) 1994-08-18 1996-02-29 Ariad Gene Therapeutics, Inc. New multimerizing agents
US6133456A (en) 1994-08-18 2000-10-17 Ariad Gene Therapeutics, Inc. Synthetic multimerizing agents
US6150527A (en) 1994-08-18 2000-11-21 Ariad Pharmaceuticals, Inc. Synthetic multimerizing agents
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
WO1996020951A1 (en) 1994-12-29 1996-07-11 Massachusetts Institute Of Technology Chimeric dna-binding proteins
US6326166B1 (en) 1995-12-29 2001-12-04 Massachusetts Institute Of Technology Chimeric DNA-binding proteins
US5681746A (en) 1994-12-30 1997-10-28 Chiron Viagene, Inc. Retroviral delivery of full length factor VIII
KR19990022651A (en) 1995-06-07 1999-03-25 데이비드 엘. 버스테인 Rapamycin-Based Control of Biological Events
US6506379B1 (en) 1995-06-07 2003-01-14 Ariad Gene Therapeutics, Inc. Intramuscular delivery of recombinant AAV
US6187757B1 (en) 1995-06-07 2001-02-13 Ariad Pharmaceuticals, Inc. Regulation of biological events using novel compounds
AU6486196A (en) 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs with altered protease sites
DE69739853D1 (en) 1996-02-28 2010-06-02 Ariad Pharma Inc SYNTHETIC RAPAMYCINE DERIVATIVES AS MULTIMIZING ACTIVE SUBSTANCES FOR CHIMERIC PROTEINS WITH DOMAINS DERIVED FROM IMMUNOPHILIN
US6723531B2 (en) 1996-04-05 2004-04-20 The Salk Institute For Biological Studies Method for modulating expression of exogenous genes in mammalian systems, and products related thereto
AU735648B2 (en) 1996-07-12 2001-07-12 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
WO1999010510A2 (en) 1997-08-26 1999-03-04 Ariad Gene Therapeutics, Inc. Fusion proteins comprising a dimerization, trimerization or tetramerization domain and an additional heterologous transcription activation, transcription repression, dna binding or ligand binding domain
US6015709A (en) 1997-08-26 2000-01-18 Ariad Pharmaceuticals, Inc. Transcriptional activators, and compositions and uses related thereto
US6479653B1 (en) 1997-08-26 2002-11-12 Ariad Gene Therapeutics, Inc. Compositions and method for regulation of transcription
AU755784B2 (en) 1998-01-15 2002-12-19 Ariad Pharmaceuticals, Inc. Regulation of biological events using multimeric chimeric proteins
US6984635B1 (en) 1998-02-13 2006-01-10 Board Of Trustees Of The Leland Stanford Jr. University Dimerizing agents, their production and use
EP1053241A1 (en) 1998-02-13 2000-11-22 President And Fellows Of Harvard College Novel dimerizing agents, their production and use
US6333318B1 (en) 1998-05-14 2001-12-25 The Salk Institute For Biological Studies Formulations useful for modulating expression of exogenous genes in mammalian systems, and products related thereto
US6258603B1 (en) 1998-06-17 2001-07-10 Rohm And Haas Company Ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
US6221349B1 (en) 1998-10-20 2001-04-24 Avigen, Inc. Adeno-associated vectors for expression of factor VIII by target cells
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US7109317B1 (en) 1998-11-06 2006-09-19 President And Fellows Of Harvard College FK506-based regulation of biological events
US7067526B1 (en) 1999-08-24 2006-06-27 Ariad Gene Therapeutics, Inc. 28-epirapalogs
ES2219388T3 (en) 1999-08-24 2004-12-01 Ariad Gene Therapeutics, Inc. 28-EPI-RAPALOGOS.
CA2392299A1 (en) * 1999-12-10 2001-06-14 Victor Rivera Methods for expression of genes in primates
WO2001070816A2 (en) 2000-03-22 2001-09-27 Rohm And Haas Company Ecdysone receptor-based inducible gene expression system
US20040033600A1 (en) 2001-03-21 2004-02-19 Palli Subba Reddy Ecdysone receptor-based inducible gene expression system
US8105825B2 (en) 2000-10-03 2012-01-31 Intrexon Corporation Multiple inducible gene regulation system
MXPA03007492A (en) 2001-02-20 2004-10-15 Rheogene Holdings Inc Chimeric retinoid x receptors and their use in a novel ecdysone receptor-based inducible gene expression system.
US9493540B2 (en) 2001-02-20 2016-11-15 Intrexon Corporation Ecdysone receptor/invertebrate retinoid X receptor-based inducible gene expression system
CA2438133C (en) 2001-02-20 2015-01-27 Rheogene, Inc. Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system
ES2422303T3 (en) 2001-02-20 2013-09-10 Intrexon Corp Novel replacement mutant receptors and their use in an inducible gene expression system based on nuclear receptors
CN102181480B (en) 2001-11-13 2016-01-27 宾夕法尼亚大学托管会 Detect and/or identify the method for the novel sequences that adeno associated virus (AAV) sequence and separation are identified
ES2602352T3 (en) 2001-12-17 2017-02-20 The Trustees Of The University Of Pennsylvania Sequences of serotype 8 of adeno-associated virus (VAA), vectors containing them and uses thereof
US20040209323A1 (en) * 2002-11-12 2004-10-21 Veritas Protein expression by codon harmonization and translational attenuation
DK2292779T3 (en) 2003-09-30 2017-02-27 Univ Pennsylvania ADENOASS-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS CONTAINING SAME AND APPLICATIONS THEREOF
US7935510B2 (en) 2004-04-30 2011-05-03 Intrexon Corporation Mutant receptors and their use in a nuclear receptor-based inducible gene expression system
CN104293835B (en) 2005-04-07 2017-07-04 宾夕法尼亚大学托管会 The method for strengthening function of gland related viral vector
KR20080031024A (en) 2005-07-21 2008-04-07 아보트 러보러터리즈 Multiple gene expression including sorf constructs and methods with polyproteins, pro-proteins, and proteolysis
EP2282764B2 (en) 2008-04-22 2024-06-12 Vib Vzw Liver-specific nucleic acid regulatory elements and methods and use thereof
US9315825B2 (en) 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
BR112012024934A2 (en) 2010-03-29 2016-12-06 Univ Pennsylvania pharmacologically induced transgene ablation systems
EP2699688A1 (en) 2011-04-20 2014-02-26 The Trustees Of The University Of Pennsylvania Regimens and compositions for aav-mediated passive immunization of airborne pathogens
WO2015012924A2 (en) * 2013-04-29 2015-01-29 The Trustees Of The University Of Pennsylvania Tissue preferential codon modified expression cassettes, vectors containing same, and use thereof
US10780182B2 (en) 2014-04-25 2020-09-22 The Trustees Of The University Of Pennsylvania Methods and compositions for treating metastatic breast cancer and other cancers in the brain
MX365658B (en) 2014-05-13 2019-06-10 Univ Pennsylvania Compositions comprising aav expressing dual antibody constructs and uses thereof.
EA201792500A1 (en) 2015-05-13 2018-04-30 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания AAV-MEDIATED EXPRESSION OF ANTIBODIES AGAINST FLU AND METHODS OF THEIR USE
EP3344294A4 (en) 2015-08-31 2019-03-20 The Trustees Of The University Of Pennsylvania Chimeric aav-anti-vegf for treating cancer in canines
US20190002915A1 (en) 2015-12-14 2019-01-03 The Trustees Of The University Of Pennsylvania Compositions and methods for regulatable antibody expression
US20180363000A1 (en) 2015-12-14 2018-12-20 The Trustees Of The University Of Pennsylvania Aav-anti pcsk9 antibody constructs and uses thereof
WO2018057916A1 (en) 2016-09-24 2018-03-29 The Trustees Of The University Of Pennsylvania Novel humanized anti-ebola antibodies useful in preventing ebola infections

Cited By (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10780182B2 (en) 2014-04-25 2020-09-22 The Trustees Of The University Of Pennsylvania Methods and compositions for treating metastatic breast cancer and other cancers in the brain
US11865187B2 (en) 2014-04-25 2024-01-09 The Trustees Of The University Of Pennsylvania Methods and compositions for treating metastatic breast cancer and other cancers in the brain
US10975140B2 (en) 2014-05-13 2021-04-13 The Trustees Of The University Of Pennsylvania Compositions comprising AAV expressing dual antibody constructs and uses thereof
US10647758B2 (en) 2014-05-13 2020-05-12 The Trustees Of The University Of Pennsylvania Compositions comprising AAV expressing dual antibody constructs and uses thereof
US10385119B2 (en) 2014-05-13 2019-08-20 Trustees Of The University Of Pennsylvania Compositions comprising AAV expressing dual antibody constructs and uses thereof
US10138295B2 (en) 2014-05-13 2018-11-27 The Trustees Of The University Of Pennsylvania Compositions comprising AAV expressing dual antibody constructs and uses thereof
US10577627B2 (en) 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
US10335466B2 (en) 2014-11-05 2019-07-02 Voyager Therapeutics, Inc. AADC polynucleotides for the treatment of parkinson's disease
US11027000B2 (en) 2014-11-05 2021-06-08 Voyager Therapeutics, Inc. AADC polynucleotides for the treatment of Parkinson's disease
US11975056B2 (en) 2014-11-05 2024-05-07 Voyager Therapeutics, Inc. AADC polynucleotides for the treatment of Parkinson's disease
US11344608B2 (en) 2014-11-12 2022-05-31 Ucl Business Ltd Factor IX gene therapy
US10413598B2 (en) 2014-11-12 2019-09-17 Ucl Business Plc Factor IX gene therapy
US10570395B2 (en) 2014-11-14 2020-02-25 Voyager Therapeutics, Inc. Modulatory polynucleotides
US10597660B2 (en) 2014-11-14 2020-03-24 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
US11542506B2 (en) 2014-11-14 2023-01-03 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
US12071625B2 (en) 2014-11-14 2024-08-27 Voyager Therapeutics, Inc. Modulatory polynucleotides
US12123002B2 (en) 2014-11-14 2024-10-22 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
US11198873B2 (en) 2014-11-14 2021-12-14 Voyager Therapeutics, Inc. Modulatory polynucleotides
US10920227B2 (en) 2014-11-14 2021-02-16 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
US11697825B2 (en) 2014-12-12 2023-07-11 Voyager Therapeutics, Inc. Compositions and methods for the production of scAAV
US11103596B2 (en) 2015-05-11 2021-08-31 Ucl Business Plc Fabry disease gene therapy
US11535665B2 (en) 2015-05-13 2022-12-27 The Trustees Of The University Of Pennsylvania AAV-mediated expression of anti-influenza antibodies and methods of use thereof
WO2017024198A1 (en) 2015-08-06 2017-02-09 The Trustees Of The University Of Pennsylvania Glp-1 and use thereof in compositions for treating metabolic diseases
US11117942B2 (en) 2015-08-31 2021-09-14 The Trustees Of The University Of Pennsylvania AAV-EPO for treating companion animals
WO2017040524A1 (en) 2015-08-31 2017-03-09 The Trustees Of The University Of Pennsylvania Aav-epo for treating companion animals
US10988519B2 (en) 2015-09-24 2021-04-27 The Trustees Of The University Of Pennsylvania Composition and method for treating complement-mediated disease
US10426845B2 (en) 2015-09-30 2019-10-01 Ucl Business Plc Diabetes gene therapy
WO2017055872A1 (en) * 2015-09-30 2017-04-06 Ucl Business Plc Diabetes gene therapy
US11273227B2 (en) 2015-10-09 2022-03-15 The Trustees Of The University Of Pennsylvania Compositions and methods useful in treating Stargardt's disease and other ocular disorders
WO2017075119A1 (en) 2015-10-28 2017-05-04 The Trustees Of The Univeresity Of Pennsylvania Intrathecal administration of adeno-associated-viral vectors for gene therapy
EP4316512A2 (en) 2015-10-28 2024-02-07 The Trustees of The University of Pennsylvania Intrathecal administration of adeno-associated-viral vectors for gene therapy
US11135313B2 (en) 2015-10-28 2021-10-05 The Trustees Of The University Of Pennsylvania Intrathecal administration of adeno-associated-viral vectors for gene therapy
US12090200B2 (en) 2016-02-08 2024-09-17 American Gene Technologies International Inc. Methods of producing cells resistant to HIV infection
US10888628B2 (en) 2016-04-15 2021-01-12 The Trustees Of The University Of Pennsylvania Gene therapy for treating hemophilia A
WO2017180861A1 (en) 2016-04-15 2017-10-19 The Trustees Of The University Of Pennsulvania Gene therapy for treating hemophilia b
WO2017180857A1 (en) 2016-04-15 2017-10-19 The Trustees Of The University Of Pennsylvania Gene therapy for treating hemophilia a
US11779656B2 (en) 2016-04-15 2023-10-10 The Trustees Of The University Of Pennsylvania Gene therapy for treating hemophilia A
US11191847B2 (en) 2016-04-15 2021-12-07 The Trustees Of The University Of Pennsylvania Gene therapy for treating hemophilia B
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
US10584337B2 (en) 2016-05-18 2020-03-10 Voyager Therapeutics, Inc. Modulatory polynucleotides
US12084659B2 (en) 2016-05-18 2024-09-10 Voyager Therapeutics, Inc. Modulatory polynucleotides
US11193129B2 (en) 2016-05-18 2021-12-07 Voyager Therapeutics, Inc. Modulatory polynucleotides
US11951121B2 (en) 2016-05-18 2024-04-09 Voyager Therapeutics, Inc. Compositions and methods for treating Huntington's disease
US11197936B2 (en) 2016-07-08 2021-12-14 The Trustees Of The University Of Pennsylvania Methods and compositions for treatment of disorders and diseases involving RDH12
WO2018011572A1 (en) * 2016-07-12 2018-01-18 The University Of Manchester Gene therapy
US11458211B2 (en) 2016-07-12 2022-10-04 The University Of Manchester Gene therapy
US11883470B2 (en) 2016-07-25 2024-01-30 The Trustees Of The University Of Pennsylvania Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof
US11298041B2 (en) 2016-08-30 2022-04-12 The Regents Of The University Of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
US11382941B2 (en) 2016-12-30 2022-07-12 The Trustees Of The University Of Pennsylvania Gene therapy for treating Phenylketonuria
WO2018126116A1 (en) 2016-12-30 2018-07-05 The Trustees Of The University Of Pennsylvania Gene therapy for treating wilson's disease
US11473106B2 (en) 2016-12-30 2022-10-18 The Trustees Of The University Of Pennsylvania Gene therapy for treating Wilson's disease
EP4361277A2 (en) 2016-12-30 2024-05-01 The Trustees of The University of Pennsylvania Gene therapy for treating wilson's disease
US11535866B2 (en) 2017-02-01 2022-12-27 The Trustees Of The University Of Pennsylvania Gene therapy for treating citrullenemia
US10786568B2 (en) 2017-02-28 2020-09-29 The Trustees Of The University Of Pennsylvania AAV mediated influenza vaccines
US11827906B2 (en) 2017-02-28 2023-11-28 The Trustees Of The University Of Pennsylvania Adeno-associated virus (AAV) clade f vector and uses therefor
US11578341B2 (en) 2017-02-28 2023-02-14 The Trustees Of The University Of Pennsylvania Compositions useful in treatment of spinal muscular atrophy
WO2018160585A2 (en) 2017-02-28 2018-09-07 The Trustees Of The University Of Pennsylvania Compositions useful in treatment of spinal muscular atrophy
WO2018160573A1 (en) 2017-02-28 2018-09-07 The Trustees Of The University Of Pennsylvania Influenza vaccines based on aav vectors
WO2018160582A1 (en) 2017-02-28 2018-09-07 The Trustees Of The University Of Pennsylvania Adeno-associated virus (aav) clade f vector and uses therefor
US11564996B2 (en) 2017-03-01 2023-01-31 The Trustees Of The University Of Pennsylvania Gene therapy for ocular disorders
US11879133B2 (en) 2017-04-24 2024-01-23 The Trustees Of The University Of Pennsylvania Gene therapy for ocular disorders
US11603542B2 (en) 2017-05-05 2023-03-14 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
US11752181B2 (en) 2017-05-05 2023-09-12 Voyager Therapeutics, Inc. Compositions and methods of treating Huntington's disease
US11591614B2 (en) 2017-05-11 2023-02-28 The Trustees Of The University Of Pennsylvania Gene therapy for ceroid lipofuscinoses
US11793887B2 (en) 2017-05-31 2023-10-24 The Trustees Of The University Of Pennsylvania Gene therapy for treating peroxisomal disorders
WO2018218359A1 (en) 2017-05-31 2018-12-06 The Trustees Of The University Of Pennsylvania Gene therapy for treating peroxisomal disorders
US11759506B2 (en) 2017-06-15 2023-09-19 Voyager Therapeutics, Inc. AADC polynucleotides for the treatment of Parkinson's disease
WO2019014061A1 (en) 2017-07-12 2019-01-17 Dow Global Technologies, Llc Compositions and methods for remediation of sulfate reducing prokaryotes
US11497576B2 (en) 2017-07-17 2022-11-15 Voyager Therapeutics, Inc. Trajectory array guide system
US11512327B2 (en) 2017-08-03 2022-11-29 Voyager Therapeutics, Inc. Compositions and methods for delivery of AAV
US12116589B2 (en) 2017-10-16 2024-10-15 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (ALS)
US11931375B2 (en) 2017-10-16 2024-03-19 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (ALS)
US11434502B2 (en) 2017-10-16 2022-09-06 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (ALS)
US11629198B2 (en) 2017-12-05 2023-04-18 The Trustees Of The University Of Pennsylvania Fusion proteins and antibodies targeting human red blood cell antigens
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
US11517631B2 (en) 2018-08-20 2022-12-06 Ucl Business Ltd Factor IX encoding nucleotides
WO2020072354A1 (en) 2018-10-01 2020-04-09 The Trustees Of The University Of Pennsylvania Compositions useful for treating gm1 gangliosidosis
WO2020176562A1 (en) 2019-02-26 2020-09-03 The Trustees Of The University Of Pennsylvania Compositions useful in treatment of krabbe disease
US20220118108A1 (en) * 2019-02-26 2022-04-21 The Trustees Of The University Of Pennsylvania Compositions useful in treatment of krabbe disease
WO2021155337A1 (en) 2020-02-02 2021-08-05 The Trustees Of The University Of Pennsylvania Compositions useful for treating gm1 gangliosidosis
EP4114439A4 (en) * 2020-03-03 2024-04-17 American Gene Technologies International Inc. On demand expression of exogenous factors in lymphocytes to treat hiv
JP2023515711A (en) * 2020-04-27 2023-04-13 ユニヴァーシティ オブ アイオワ リサーチ ファウンデーション Compositions and methods for the treatment of cystic fibrosis
WO2021231443A1 (en) 2020-05-12 2021-11-18 The Trustees Of The University Of Pennsylvania Compositions useful in treatment of krabbe disease
WO2022036220A1 (en) 2020-08-14 2022-02-17 The Trustees Of The University Of Pennsylvania Novel aav capsids and compositions containing same
WO2022046815A1 (en) 2020-08-24 2022-03-03 The Trustees Of The University Of Pennsylvania Viral vectors encoding glp-1 receptor agonist fusions and uses thereof in treating metabolic diseases
WO2022060916A1 (en) * 2020-09-15 2022-03-24 Regenxbio Inc. Vectorized antibodies for anti-viral therapy
WO2022076582A1 (en) 2020-10-07 2022-04-14 Regenxbio Inc. Gene therapy for ocular manifestations of cln2 disease
WO2022076803A1 (en) 2020-10-09 2022-04-14 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of fabry disease
WO2022094180A1 (en) 2020-10-29 2022-05-05 The Trustees Of The University Of Pennsylvania Aav capsids and compositions containing same
WO2022165313A1 (en) 2021-02-01 2022-08-04 Regenxbio Inc. Gene therapy for neuronal ceroid lipofuscinoses
WO2022232267A1 (en) 2021-04-27 2022-11-03 The Trustees Of The University Of Pennsylvania Porcine-derived adeno-associated virus capsids and uses thereof
WO2023056399A1 (en) 2021-10-02 2023-04-06 The Trustees Of The University Of Pennsylvania Novel aav capsids and compositions containing same
WO2023102517A1 (en) 2021-12-02 2023-06-08 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of fabry disease
WO2023125481A1 (en) 2021-12-28 2023-07-06 成都弘基生物科技有限公司 Modified aav capsid protein and use thereof
WO2023147304A1 (en) 2022-01-25 2023-08-03 The Trustees Of The University Of Pennsylvania Aav capsids for improved heart transduction and detargeting of liver
WO2023240236A1 (en) 2022-06-10 2023-12-14 Voyager Therapeutics, Inc. Compositions and methods for the treatment of spinal muscular atrophy related disorders
US12146150B2 (en) 2022-09-13 2024-11-19 Voyager Therapeutics, Inc. Rescue of central and peripheral neurological phenotype of friedreich's ataxia by intravenous delivery
WO2024069549A1 (en) 2022-09-29 2024-04-04 Touchlight Aquaculture Limited Vaccine construct and uses thereof
CN116103320A (en) * 2022-11-16 2023-05-12 深圳万可森生物科技有限公司 Optimization of encoding gene of rhabdovirus G2 protein of weever
WO2024105638A1 (en) 2022-11-18 2024-05-23 Jcr Pharmaceuticals Co., Ltd. Recombinant aav vectors and methods for treatment of hunter syndrome

Also Published As

Publication number Publication date
US10647998B2 (en) 2020-05-12
US20170292132A1 (en) 2017-10-12
WO2015012924A3 (en) 2015-03-19
US20160083748A1 (en) 2016-03-24
US9719106B2 (en) 2017-08-01

Similar Documents

Publication Publication Date Title
US10647998B2 (en) Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof
US10947561B2 (en) Method of increasing the function of an AAV vector
US20220154208A1 (en) Constructs and methods for delivering molecules via viral vectors with blunted innate immune responses
CA2469053C (en) Adeno-associated virus (aav) serotype 9 sequences, vectors containing same, and uses therefor
US20090317417A1 (en) Modified AAV Vectors Having Reduced Capsid Immunogenicity and Use Thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14828959

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 14787622

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 14828959

Country of ref document: EP

Kind code of ref document: A2